• Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report.
    • di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A.
    • Front Oncol. 2023 Feb 20;13:1139372. doi: 10.3389/fonc.2023.1139372.
    • Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    • Liede A, Sebby W, Miriyala AKR, Potluri R, Mazumder D, Ghosh A, Papademetriou E, Kilpatrick R, Tyczynski JE.
    • BMC Cancer. 2023 Jan 24;23(1):78. doi: 10.1186/s12885-023-10554-6.
    • Novel Agents in the Adjuvant Setting: PARP Inhibitors.
    • Geyer C, Krop IE.
    • OncLive. OncLive NewsNetwork. 2023 Jan 18.
    • Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
    • Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V.
    • Cancer Treat Rev. 2023 Jan 6;114:102511. doi: 10.1016/j.ctrv.2023.102511. Epub ahead of print.
    • Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    • Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN.
    • Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739-2. doi: 10.1016/S1470-2045(22)00739-2. Epub ahead of print.

    Related:

    •• Identifier: NCT02595905: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases. (ClinicalTrials.gov . Accessed 2023 Jan 7.)

    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.
    • Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
    • Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, Lin Y, Liu Z, Cao Y, Zhang G, Shang S, Zhang Y, Wang K.
    • JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337.

    Related:

    •• Identifier: NCT03154749: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 18.)

    • Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    • Maksimenko J, Rodrigues PP, Nakazawa-Miklaševiča M, Pinto D, Miklaševičs E, Trofimovičs G, Gardovskis J, Cardoso F, Cardoso MJ.
    • JMIR Form Res. 2022 Dec 29;6(12):e37144. doi: 10.2196/37144.
    • Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer.
    • Perez-Villatoro F, Oikkonen J, Casado J, Chernenko A, Gulhan DC, Tumiati M, Li Y, Lavikka K, Hietanen S, Hynninen J, Haltia UM, Tyrmi JS, Laivuori H, Konstantinopoulos PA, Hautaniemi S, Kauppi L, Färkkilä A.
    • NPJ Precis Oncol. 2022 Dec 29;6(1):96. doi: 10.1038/s41698-022-00339-8.
    • All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    • Wu HL, Luo ZY, He ZL, Gong Y, Mo M, Ming WK, Liu GY.
    • Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111-y. Epub ahead of print.
    • Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy.
    • Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, Combi F, Cabitza E, Caggia F, Barbieri E, Barbolini M, Moscetti L, Omarini C, Piacentini F, Tazzioli G, Dominici M, Cortesi L.
    • Front Oncol. 2022 Dec 1;12:1016295. doi: 10.3389/fonc.2022.1016295.
    • Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    • Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5228. Epub ahead of print.

    •• Identifier: NCT03330405: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Development of a novel BRCAness score that predicts response to PARP inhibitors.
    • Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, Yamamoto S, Narui K, Chishima T, Ishikawa T, Endo I, Takabe K.
    • Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.
    • Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
    • Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA.
    • JCO Precis Oncol. [2022 Nov 3];6:e2200309. doi: 10.1200/PO.22.00309.
    • Case report
    • Compounds from Diverse Natural Origin against Triple-Negative Breast Cancer: A Comprehensive Review.
    • Ramasamy T, Priyankha S, Kannan M, Prakash M, Selvam C.
    • Chem Biol Drug Des. 2022 Nov 2. doi: 10.1111/cbdd.14172. Epub ahead of print.
    • Review
    • Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    • Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C, Curigliano G, Tolaney SM, Barroso-Sousa R.
    • Cancer Treat Rev. 2022 Nov;110:102459. doi: 10.1016/j.ctrv.2022.102459. Epub 2022 Aug 18.
    • Review
    • Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
    • Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y.
    • JAMA Oncol. 2022 Oct 27. doi: 10.1001/jamaoncol.2022.5074. Epub ahead of print.

    Related:

    •• Identifier: NCT03109080: Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP). (ClinicalTrials.gov . Accessed 2022 Oct 31.)

    • Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance.
    • Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G.
    • Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2139176. Epub ahead of print.
    • Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
    • Breast. 2022 Oct 18:S0960-9776(22)00174-6. doi: 10.1016/j.breast.2022.10.009. Epub ahead of print.
    • Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
    • Lin C, Cui J, Peng Z, Qian K, Wu R, Cheng Y, Yin W.
    • Eur J Med Res. 2022 Oct 15;27(1):201. doi: 10.1186/s40001-022-00839-0.
    • Emerging Targeted Therapies for Early Breast Cancer.
    • Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM.
    • Drugs. 2022 Oct 7. doi: 10.1007/s40265-022-01781-5. Epub ahead of print.
    • Review
    • CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    • Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
    • Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.
    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Oct;29(11):6504-6507. doi: 10.1245/s10434-022-12048-4. Epub 2022 Jun 18.

    Related:

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
    • Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D.
    • Cancer Treat Rev. 2022 Sep 28;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub ahead of print.
    • Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
    • Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O.
    • J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595.
    • Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    • Mailliez A, D'Hondt V, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero JM, Petit T, Mouret-Reynier MA, Eymard JC, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Frenel ES, De la Motte Rouge T, Simon G, Jacot W, Delaloge S.
    • Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34304. Epub ahead of print.
    • BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
    • Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G, Garganese G, Corrado G, Di Leone A, Generali D, Fragomeni SM, D'Angelo T, Franceschini G, Masetti R, Fabi A, Mulè A, Santoro A, Belli P, Tortora G, Scambia G, Paris I.
    • Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14194571.
    • Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Pinto L, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2022 Sep 9;20(1):34. doi: 10.1186/s13053-022-00242-0.
    • PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
    • Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F.
    • Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332.
    • A progressive and refractory case of breast cancer with Cowden syndrome.
    • Sueta A, Takeno M, Goto-Yamaguchi L, Tomiguchi M, Inao T, Yamamoto-Ibusuki M, Yamamoto Y.
    • World J Surg Oncol. 2022 Sep 3;20(1):279. doi: 10.1186/s12957-022-02745-5.
    • A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.
    • Jia X, Wang K, Xu L, Li N, Zhao Z, Li M.
    • Breast. 2022 Sep 2;66:31-39. doi: 10.1016/j.breast.2022.08.012. Epub ahead of print.
    • Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
    • Garufi G, Carbognin L, Schettini F, Seguí E, Di Leone A, Franco A, Paris I, Scambia G, Tortora G, Fabi A.
    • Cancers (Basel). 2022 Aug 23;14(17):4064. doi: 10.3390/cancers14174064.
    • Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis.
    • Leung JH, Tai YS, Wang SY, Tsung-Chin H, Yip FH, Chan AL, Yu-Chen H.
    • Expert Opin Drug Saf. 2022 Aug 23. doi: 10.1080/14740338.2022.2116001. Epub ahead of print.
    • Meta-Analysis
    • Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
    • Lucas MW, Kelly CM.
    • Cancer Manag Res. 2022 Aug 17;14:2493-2506. doi: 10.2147/CMAR.S341466.
    • Triple negative breast cancer: approved treatment options and their mechanisms of action.
    • Mandapati A, Lukong KE.
    • J Cancer Res Clin Oncol. 2022 Aug 17. doi: 10.1007/s00432-022-04189-6. Epub ahead of print.
    • The landscape of systemic therapy for early stage triple negative breast cancer.
    • Lu JY, Alvarez Soto A, Anampa JD.
    • Expert Opin Pharmacother. 2022 Aug;23(11):1291-1303. doi: 10.1080/14656566.2022.2095902. Epub 2022 Jul 25.
    • Review
    • Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    • de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
    • J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30.
    • Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
    • Yoder R, Kimler BF, Staley JM, Schwensen K, Wang YY, Finke K, O'Dea A, Nye L, Elia M, Crane G, McKittrick R, Pluenneke R, Madhusudhana S, Beck L, Shrestha A, Corum L, Marsico M, Stecklein SR, Godwin AK, Khan QJ, Sharma P.
    • NPJ Breast Cancer. 2022 Jul 11;8(1):80. doi: 10.1038/s41523-022-00448-4.
    • Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer.
    • Pauls M, Chia S, LeVasseur N.
    • Curr Oncol. 2022 Jul 7;29(7):4748-4767. doi: 10.3390/curroncol29070377.
    • Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
    • MacDonald I, Nixon NA, Khan OF.
    • Curr Oncol. 2022 Jul 7;29(7):4768-4778. doi: 10.3390/curroncol29070378.
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Related:

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.
    • Wang X, Hu N, Cui L, Si Y, Yue J, Zheng F, Kang Y, Yuan P.
    • Curr Cancer Drug Targets. 2022 [Jul];22(6):530-536. doi: 10.2174/1568009622666220214092207.
    • A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
    • Huang Y, Dai X, Guan Z, Liu D, Ren L, Chen M, Zeng Z, Jiang J, Luo Y, He Y, Huang M, Zhao C.
    • Int J Pharm. 2022 Jun 25;622:121897. doi: 10.1016/j.ijpharm.2022.121897. Epub 2022 Jun 8.
    • Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses.
    • Green-Tripp G, Nattress C, Halldén G.
    • Front Mol Biosci. 2022 Jun 24;9:901392. doi: 10.3389/fmolb.2022.901392.
    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.
    • Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
    • Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R.
    • Eur J Med Chem. 2022 Jun 5;236:114321. doi: 10.1016/j.ejmech.2022.114321. Epub 2022 Apr 3.
    • SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    • Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
    • J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
    • Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    • Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
    • Breast. 2022 Jun;63:77-84. doi: 10.1016/j.breast.2022.03.011. Epub 2022 Mar 19.
    • Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
    • Xiao Y, Gao W.
    • Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340.
    • Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
    • Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L.
    • J Med Chem. 2022 May 12;65(9):6803-6825. doi: 10.1021/acs.jmedchem.2c00135. Epub 2022 Apr 20.
    • OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
    • Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodríguez-Perales S, Helleday T, Benítez-Buelga C, Benítez J, Osorio A.
    • Front Oncol. 2022 May 10;12:888810. doi: 10.3389/fonc.2022.888810.
    • Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    • Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
    • Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.
    • Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    • Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.
    • BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1.
    • Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    • Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer EL.
    • Clin Cancer Res. 2022 Apr 14;28(8):1493-1499. doi: 10.1158/1078-0432.CCR-21-3045.
    • Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    • Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186.
    • Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
    • Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V.
    • ESMO Open. 2022 Apr;7(2):100409. doi: 10.1016/j.esmoop.2022.100409. Epub 2022 Feb 26. Erratum in: ESMO Open. 2022 Apr 7;7(3):100472.
    • Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
    • Desnoyers A, Nadler M, Wilson BE, Stajer S, Amir E.
    • NPJ Breast Cancer. 2022 Mar 31;8(1):43. doi: 10.1038/s41523-022-00405-1.
    • PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients' CTCs.
    • Sklias T, Vardas V, Pantazaka E, Christopoulou A, Georgoulias V, Kotsakis A, Vasilopoulos Y, Kallergi G.
    • Cancers (Basel). 2022 Mar 29;14(7):1731. doi: 10.3390/cancers14071731.
    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    • Guney Eskiler G, Ozturk M.
    • Cell Signal. 2022 Mar;91:110229. doi: 10.1016/j.cellsig.2021.110229. Epub 2021 Dec 24.
    • Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
    • Vaid AK, Deshmukh C, Rohatgi N, Ghosh J.
    • Indian J Cancer. 2022 Mar;59(Supplement):S130-S141. doi: 10.4103/ijc.IJC_30_21.
    • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
    • Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA.
    • JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280.
    • A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
    • Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A.
    • Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31.
    • Review
    • Post-Neoadjuvant Treatment Strategies in Breast Cancer.
    • Matuschek C, Jazmati D, Bölke E, Tamaskovics B, Corradini S, Budach W, Krug D, Mohrmann S, Ruckhäberle E, Fehm T, Nestle Krämling C, Dommach M, Haussmann J.
    • Cancers (Basel). 2022 Feb 28;14(5):1246. doi: 10.3390/cancers14051246.
    • Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
    • Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z.
    • Cancers (Basel). 2022 Feb 28;14(5):1253. doi: 10.3390/cancers14051253.
    • Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    • Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B.
    • J Pers Med. 2022 Feb 21;12(2):323. doi: 10.3390/jpm12020323.
    • Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    • Landry I, Sumbly V, Vest M.
    • Cureus. 2022 Feb 7;14(2):e21970. doi: 10.7759/cureus.21970.
    • Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
    • Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A.
    • Int J Mol Sci. 2022 Jan 31;23(3):1665. doi: 10.3390/ijms23031665.
    • Real-world evidence of the management and prognosis of young women (<40 years) with de novo metastatic breast cancer.
    • Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, De La Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Sébastien Frenel J.
    • Ther Adv Med Oncol. 2022 Jan 21;14:17588359211070362. doi: 10.1177/17588359211070362.
    • FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer.
    • Bachmann HS, Jung D, Link T, Arnold A, Kantelhardt E, Thomssen C, Wimberger P, Vetter M, Kuhlmann JD.
    • Cancers (Basel). 2022 Jan 18;14(3):468. doi: 10.3390/cancers14030468.
    • Construction and Validation of a Prognostic Risk Model for Triple Negative Breast Cancer Based on Autophagy-Related Genes.
    • Jia R, Yan C, Liu Q.
    • Front Oncol. 2022 Jan 10;10:829045. doi: 10.3389/fonc.2022.829045.
    • Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis.
    • Hao KJ, Jia X, Dai WT, Huo ZM, Zhang HQ, Liu JW, Wang XB.
    • Front Oncol. 2022 Jan 3;11:689553. doi: 10.3389/fonc.2021.689553.
    • Platinum-based systematic therapy in triple-negative breast cancer.
    • Zhu Y, Hu Y, Tang C, Guan X, Zhang W.
    • Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188678. doi: 10.1016/j.bbcan.2022.188678. Epub 2022 Jan 10.
    • Review
    • qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Zuo K, Yuan X, Liang X, Sun X, Liu S, Connell PP, Li X, Yang W.
    • Breast Cancer Res Treat. 2022 Jan;191(2):335-344. doi: 10.1007/s10549-021-06442-x. Epub 2021 Nov 19.
    • Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
    • Zheng F, Du F, Wang W, Wang Y, Li M, Zhao J, Wang X, Yue J, Wang J, Yang Z, Cai R, Ma F, Fan Y, Li Q, Zhang P, Xu B, Yuan P.
    • Breast Cancer Res Treat. 2022 Jan;191(1):97-105. doi: 10.1007/s10549-021-06401-6. Epub 2021 Oct 14.
    • Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
    • Vidra R, Nemes A, Vidrean A, Pintea S, Tintari S, Deac A, Ciuleanu T.
    • Exp Ther Med. 2022 Jan;23(1):91. doi: 10.3892/etm.2021.11014. Epub 2021 Nov 26.
    • FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
    • Wang SP, Wu SQ, Huang SH, Tang YX, Meng LQ, Liu F, Zhu QH, Xu YG.
    • Cell Death Dis. 2021 Dec 8;12(12):1138. doi: 10.1038/s41419-021-04434-9.
    • Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
    • Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y, Qi X.
    • Front Pharmacol. 2021 Dec 6;12:770663. doi: 10.3389/fphar.2021.770663.
    • Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
    • Yordanova M, Hubert A, Hassan S.
    • Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.
    • Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    • Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V.
    • Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.
    • Influence of germline BRCA genotype on the survival of patients with triple-negative breast cancer.
    • Villarreal-Garza C, Ferrigno AS, Aranda-Gutierrez A, Frankel PH, Ruel NH, Fonseca A, Narod S, Chavarri-Guerra Y, Sifuentes E, Magallanes-Hoyos MC, Herzog J, Castillo D, Alvarez-Gomez RM, Mohar-Betancourt A, Weitzel JN.
    • Cancer Res Commun. 2021 Dec;1(3):140-147. doi: 10.1158/2767-9764.crc-21-0099. Epub 2021 Dec 8.
    • Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
    • Sakach E, O'Regan R, Meisel J, Li X.
    • Clin Breast Cancer. 2021 Dec;21(6):509-520. doi: 10.1016/j.clbc.2021.09.003. Epub 2021 Sep 17.
    • Review
    • CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.
    • Saleh L, Wilson C, Holen I.
    • MedComm (2020). 2021 Nov 17;2(4):514-530. doi: 10.1002/mco2.97. eCollection 2021 Dec.
    • Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
    • Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F.
    • Front Oncol. 2021 Nov 25;11:769280. doi: 10.3389/fonc.2021.769280.
    • Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
    • Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE Jr, Loibl S, Stover DG.
    • NPJ Breast Cancer. 2021 Nov 11;7(1):142. doi: 10.1038/s41523-021-00349-y.
    • Examining the Prevalence of Homologous Recombination Repair Defects in ER+ Breast Cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S35-S36. doi: 10.1016/j.ijrobp.2021.07.106.
    • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    • Li Y, Zhan Z, Yin X, Fu S, Deng X.
    • Front Oncol. 2021 Oct 28;11:731535. doi: 10.3389/fonc.2021.731535.
    • Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    • Liu X, Wu K, Zheng D, Luo C, Fan Y, Zhong X, Zheng H.
    • Front Oncol. 2021 Oct 28;11:742139. doi: 10.3389/fonc.2021.742139.
    • Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
    • Huang X, Wang X, Qian H, Jin X, Jiang G.
    • Evid Based Complement Alternat Med. 2021 Oct 22;2021:5314016. doi: 10.1155/2021/5314016.
    • Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance.
    • Singh DD, Parveen A, Yadav DK.
    • Biomedicines. 2021 Oct 21;9(11):1512. doi: 10.3390/biomedicines9111512.
    • Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
    • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI.
    • NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w.
    • PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.
    • Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW.
    • J Pers Med. 2021 Oct 8;11(10):1009. doi: 10.3390/jpm11101009.
    • Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    • Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M; Breast Cancer Therapy Expert Group (BCTEG).
    • Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29.
    • Review
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
    • Wang W, Zhang W, Wu J, Zhou Z, Ma J.
    • Clin Exp Med. 2021 Sep 14. doi: 10.1007/s10238-021-00757-1. Epub ahead of print.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Genetic testing in patients with triple-negative or hereditary breast cancer.
    • Bernstein-Molho R, Evron E, Yerushalmi R, Paluch-Shimon S.
    • Curr Opin Oncol. 2021 Sep 1. doi: 10.1097/CCO.0000000000000784. Epub ahead of print.
    • Review
    • Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
    • Marijon H, Gery S, Chang H, Landesman Y, Shacham S, Lee DH, de Gramont A, Koeffler HP.
    • Oncotarget. 2021 Aug 31;12(18):1749-1762. doi: 10.18632/oncotarget.28047.
    • Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
    • Wang C, Qu L, Li S, Yin F, Ji L, Peng W, Luo H, Lu D, Liu X, Chen X, Kong L, Wang X.
    • J Med Chem. 2021 Aug 29. doi: 10.1021/acs.jmedchem.1c00567. Epub ahead of print.
    • Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors.
    • Davidson CD, Gillis NE, Carr FE.
    • Cancers (Basel). 2021 Aug 24;13(17):4254. doi: 10.3390/cancers13174254.
    • Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
    • Hongthong K, Nhukeaw T, Temboot P, Dyson PJ, Ratanaphan A.
    • Heliyon. 2021 Aug 10;7(8):e07749. doi: 10.1016/j.heliyon.2021.e07749.
    • Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    • Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, Morrow M, Berek JS, Hofer TP, Katz SJ, Ward KC.
    • J Natl Cancer Inst. 2021 Aug 9:djab151. doi: 10.1093/jnci/djab151. Epub ahead of print.
    • Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies.
    • Kanwal B.
    • Cureus. 2021 Jul 26;13(7):e16636. doi: 10.7759/cureus.16636.
    • Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.
    • Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP.
    • Front Oncol. 2021 Jul 22;11:694793. doi: 10.3389/fonc.2021.694793.
    • Investigational Drug Treatments for Triple-Negative Breast Cancer.
    • Damaskos C, Garmpis N, Garmpi A, Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D, Antoniou EA, Karamouzis MV, Nikolettos N, Kontzoglou K, Patsouras A, Voutyritsa E, Syllaios A, Koustas E, Trakas N, Dimitroulis D.
    • J Pers Med. 2021 Jul 10;11(7):652. doi: 10.3390/jpm11070652.
    • Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.
    • Dameri M, Ferrando L, Cirmena G, Vernieri C, Pruneri G, Ballestrero A, Zoppoli G.
    • Int J Mol Sci. 2021 Jul 1;22(13):7154. doi: 10.3390/ijms22137154.
    • Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
    • Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D.
    • Front Oncol. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776.
    • Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
    • Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S.
    • Diagnostics (Basel). 2021 Jun 23;11(7):E1144. doi: 10.3390/diagnostics11071144.
    • Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.
    • Wang Y, van den Broek AJ, Schmidt MK.
    • Breast Cancer Res Treat.2021 Jun 16. doi: 10.1007/s10549-021-06289-2. Epub ahead of print.
    • Letter, Comment

    Related:

    Review:

    Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.

    • A DNA methylation-based liquid biopsy for triple-negative breast cancer.
    • Cristall K, Bidard FC, Pierga JY, Rauh MJ, Popova T, Sebbag C, Lantz O, Stern MH, Mueller CR.
    • NPJ Precis Oncol. 2021 Jun 16;5(1):53. doi: 10.1038/s41698-021-00198-9.
    • Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA.
    • Ann Oncol. 2021 Jun 8:S0923-7534(21)02047-0. doi: 10.1016/j.annonc.2021.06.002. Epub ahead of print.
    • A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    • Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K.
    • Cancers (Basel). 2021 May 16;13(10):2401. doi: 10.3390/cancers13102401.
    • Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    • Nagayama A, Vidula N, Bardia A.
    • Oncology (Williston Park). 2021 May 13;35(5):249-254. doi: 10.46883/ONC.2021.3505.0249.
    • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
    • Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H.
    • Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.
    • Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    • Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, Li X, Hou W, Bao D, Ren L, Yang J, Wang S, Qiu Y, Zhou F, Liu Z, Zhu S, Zhang L, Qing T, Wang Y, Yu Y, Wu J, Hu X, Shi L.
    • Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.
    • A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
    • Wu R, Adachi K, Koyama Y, Orimoto K, Okazaki M, Asaoka M, Teraoka S, Ueda A, Miyahara K, Kawate T, Kaise H, Yamada K, Sato E, Ishikawa T.
    • J Surg Case Rep. 2021 Apr 14;2021(4):rjab018. doi: 10.1093/jscr/rjab018.
    • Research advances and new challenges in overcoming triple-negative breast cancer.
    • Zong Y, Pegram M.
    • Cancer Drug Resist. 2021;4(3):517-542. doi: 10.20517/cdr.2021.04. Epub 2021 Apr 8.
    • Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    • Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, Jiang Y, Shao Z, Wang Z.
    • J Exp Clin Cancer Res. 2021 Apr 8;40(1):122. doi: 10.1186/s13046-021-01930-w.
    • Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
    • Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K.
    • Cancers (Basel). 2021 Apr 1;13(7):1656. doi: 10.3390/cancers13071656.
    • Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
    • Liu M, Xie F, Liu M, Zhang Y, Wang S.
    • Breast Cancer Res Treat. 2021 Apr;186(3):591-605. doi: 10.1007/s10549-021-06104-y. Epub 2021 Feb 9.
    • Review

    Related:

    Letter, Comment:

    Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.

    • Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
    • Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Svoboda M, Poprach A.
    • Cancers (Basel). 2021 Mar 30;13(7):1586. doi: 10.3390/cancers13071586.
    • Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    • Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S.
    • Sci Rep. 2021 Mar 29;11(1):7064. doi: 10.1038/s41598-021-85962-4.
    • Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
    • Schick J, Ritchie RP, Restini C.
    • Breast Cancer (Auckl). 2021 Mar 24;15:1178223421995854. doi: 10.1177/1178223421995854.
    • Overview of recent advances in metastatic triple negative breast cancer.
    • O'Reilly D, Sendi MA, Kelly CM.
    • World J Clin Oncol. 2021 Mar 24;12(3):164-182. doi: 10.5306/wjco.v12.i3.164.
    • Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
    • Cipriano É, Mesquita A.
    • Breast Cancer (Auckl). 2021 Mar 22;15:11782234211002491. doi: 10.1177/11782234211002491.
    • Role of Platinums in Triple-Negative Breast Cancer.
    • Lynce F, Nunes R.
    • Curr Oncol Rep. 2021 Mar 22;23(5):50. doi: 10.1007/s11912-021-01041-x.
    • Review
    • Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    • Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
    • NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w.
    • An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    • Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES.
    • Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9.
    • Contralateral Prophylactic Mastectomy in Patients with Breast Cancer.
    • Noditi A, Caragheorghe G, Stoleru S, Blidaru A, Bordea CI.
    • Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):73-83.
    • Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
    • Lobanova OE, Rossokha ZI, Medvedieva NL, Cheshuk VE, Vereshchako RI, Vershyhora VO, Fishchuk LY, Zakhartseva LM, Gorovenko NG.
    • Exp Oncol. 2021 Mar;43(1):56-60. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.15703.
    • Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    • Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
    • Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.
    • Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    • Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
    • J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.
    • Clinicopathological Correlates of ?d T Cell Infiltration in Triple-Negative Breast Cancer.
    • Boissière-Michot F, Chabab G, Mollevi C, Guiu S, Lopez-Crapez E, Ramos J, Bonnefoy N, Lafont V, Jacot W.
    • Cancers (Basel). 2021 Feb 12;13(4):765. doi: 10.3390/cancers13040765.
    • Molecular analyses of triple-negative breast cancer in the young and elderly.
    • Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
    • Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Sacituzumab Govitecan in Patients With Metastatic TNBC.
    • Vahdat L.
    • Medscape. Oncology Decision Point. 2021 Feb 3.
    • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    • Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Duc AN, Chui SY, Husain A, Winer EP, Adams S, Schmid P.
    • J Natl Cancer Inst. 2021 Feb 1:djab004. doi: 10.1093/jnci/djab004. Epub ahead of print.
    • A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
    • Huang L, Lang GT, Liu Q, Shi JX, Shao ZM, Cao AY.
    • Ann Transl Med. 2021 Feb;9(4):301. doi: 10.21037/atm-20-4852.
    • Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    • Di Leone A, Fragomeni SM, Scardina L, Ionta L, Mulè A, Magno S, Terribile D, Masetti R, Franceschini G.
    • Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1910-1915. doi: 10.26355/eurrev_202102_25087.
    • Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review.
    • Lam TC.
    • J Immunother Precis Oncol. 2021 Jan 29 [eCollection 2021 Feb];4(1):16-20. doi: 10.36401/JIPO-20-24.
    • Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    • Chen Z, Wang X, Li X, Zhou Y, Chen K.
    • J Int Med Res. 2021 Feb;49(2):300060521991019. doi: 10.1177/0300060521991019.
    • Possible Beneficial Effects of N-Acetylcysteine for Treatment of Triple-Negative Breast Cancer.
    • Kwon Y.
    • Antioxidants (Basel). 2021 Jan 24;10(2):169. doi: 10.3390/antiox10020169.
    • ASCO 2020: highlights in breast cancer.
    • Bartsch R.
    • Memo. 2021 Jan 24:1-4. doi: 10.1007/s12254-021-00674-9. Epub ahead of print.
    • Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
    • Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, Coussy F, Sablin MP, Debled M, Lefeuvre-Plesse C, Goncalves A, Reynier MM, Jacot W, You B, Barthelemy P, Verret B, Isambert N, Tchiknavorian X, Levy C, Thery JC, L'Haridon T, Ferrero JM, Mege A, Del Piano F, Rouleau E, Tran-Dien A, Adam J, Lusque A, Jimenez M, Jacquet A, Garberis I, Andre F.
    • Nat Med. 2021 Jan 18. doi: 10.1038/s41591-020-01189-2. Epub ahead of print.
    • Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection.
    • Brown JM, Wasson MD, Marcato P.
    • Cancers (Basel). 2021 Jan 15;13(2):296. doi: 10.3390/cancers13020296.
    • Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer.
    • Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A.
    • Front Oncol. 2021 Jan 11;10:574813. doi: 10.3389/fonc.2020.574813.
    • Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
    • Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J.
    • Sci Rep. 2021 Jan 8;11(1):82. doi: 10.1038/s41598-020-80081-y.
    • Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    • Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD.
    • PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025.
    • PARPi, immunothérapies et anticorps monoclonaux conjugués dans les cancers du sein triple-négatifs [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    • Dalenc F, Sarradin V, Nicolaï V, Franchet C, Ung M.
    • Bull Cancer. 2021 Jan 6:S0007-4551(20)30504-X. French. doi: 10.1016/j.bulcan.2020.11.007. Epub ahead of print.
    • Review. [Article in French]
    • Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.
    • Brown LC, Salgado R, Luen SJ, Savas P, Loi S.
    • Cancer J. 2021 Jan-Feb 01;27(1):25-31. doi: 10.1097/PPO.0000000000000501.
    • Review
    • PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    • Layman RM, Arun B.
    • Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.
    • Review
    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2021 Jan;32(1):58-65. doi: 10.1016/j.annonc.2020.10.475. Epub 2020 Oct 21.
    • [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
    • Tsunoda Y, Sasaki A, Sakamoto N, Haruyama Y, Nashimoto M, Koshida Y, Fukuma E.
    • Gan To Kagaku Ryoho. 2021 Jan;48(1):53-56.
    • [Article in Japanese]
    • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
    • Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.
    • Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14.

    Related:

    Research news: PARP Inhibitor Breast Cancer Treatments May Be Improved by Targeting Immunosuppressive Macrophages (Clinical OMICs)

    • Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    • Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A.
    • ESMO Open. 2020 Dec 31;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. Epub ahead of print.
    • Immunosuppressive Macrophages Limit PARP Inhibitor Efficacy in TNBC.
    • [No author given]
    • Cancer Discov. 2020 Dec 30:CD-RW2020-185. doi: 10.1158/2159-8290.CD-RW2020-185. Epub ahead of print.
    • Research news
    • XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
    • Ali R, Alblihy A, Toss MS, Algethami M, Al Sunni R, Green AR, Rakha EA, Madhusudan S.
    • Ther Adv Med Oncol. 2020 Dec 21;12:1758835920974201. doi: 10.1177/1758835920974201.
    • Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status.
    • Hopkins C.
    • Precision Oncology News. 2020 Dec 11.
    • Conference news
    • In Patients With Metastatic TNBC and a Deleterious BRCA Mutation, How Do You Decide Between a PARPi and an Immunotherapy-Based Combination as Initial Therapy?
    • Domchek S.
    • Medscape. Oncology Decision Point. 2020 Dec 9.
    • Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer.
    • Cheng HW, Chiang CS, Ho HY, Chou SH, Lai YH, Shyu WC, Chen SY.
    • J Control Release. 2020 Dec 2:S0168-3659(20)30718-5. doi: 10.1016/j.jconrel.2020.11.061. Epub ahead of print.
    • Novel therapies for triple-negative breast cancer.
    • Nanda R.
    • Clin Adv Hematol Oncol. 2020 Dec;18(12):799-801.
    • Triple-negative breast cancer therapy: Current and future perspectives (Review).
    • Won KA, Spruck C.
    • Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16.
    • A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities.
    • Webb MJ, Kukard C.
    • Integr Cancer Ther. 2020 Jan-Dec;19:1534735420975861. doi: 10.1177/1534735420975861. [First Published November 27, 2020.]
    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.
    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.
    • Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
    • Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, de la Cruz-Montoya A, Porras Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Robles-Estrada M, Bargalló-Rocha E, Cabrera-Galeana P, Ramos-Ramírez M, Chirino YI, Alonso Herrera L, Terrazas LI, Oliver J, Frecha C, Perdomo S, Vaca-Paniagua F.
    • Genes (Basel). 2020 Nov 19;11(11):E1367. doi: 10.3390/genes11111367.
    • Triple-negative breast cancer: promising prognostic biomarkers currently in development.
    • Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N.
    • Expert Rev Anticancer Ther. 2020 Nov 16. doi: 10.1080/14737140.2021.1840984. Epub ahead of print.
    • Review
    • A review of current progress in triple-negative breast cancer therapy.
    • Shen M, Pan H, Chen Y, Xu YH, Yang W, Wu Z.
    • Open Med (Wars). 2020 Nov 14;15(1):1143-1149. doi: 10.1515/med-2020-0138.
    • Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis.
    • Wang CJ, Xu Y, Lin Y, Zhu HJ, Zhou YD, Mao F, Zhang XH, Huang X, Zhong Y, Sun Q, Li CG.
    • Front Oncol. 2020 Nov 9;10:592998. doi: 10.3389/fonc.2020.592998.
    • Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
    • Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W.
    • Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.
    • Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer.
    • Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, Chen C, Lin Y, Lu T, Zhao B, Wang C, Sun Q.
    • Front Oncol. 2020 Oct 30;10:583314. doi: 10.3389/fonc.2020.583314. PMID: 33194720; PMCID: PMC7662137.
    • Innovations in targeted therapies for triple negative breast cancer.
    • McCann KE, Hurvitz SA.
    • Curr Opin Obstet Gynecol. 2020 Oct 21. doi: 10.1097/GCO.0000000000000671. Epub ahead of print.
    • Review
    • Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative.
    • Vidula N, Ellisen LW, Bardia A.
    • J Natl Compr Canc Netw. 2020 Oct 15:1-9. doi: 10.6004/jnccn.2020.7600. Epub ahead of print.
    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.
    • Was ist neu bei der Diagnostik und Therapie des Mammakarzinoms? – Aktuelle Standards in der Behandlung von Brustkrebs [Breast cancer - state of the art - Short overview of the current standard of treatment].
    • Albert A, Stüber T, Bauer J, Wöckel A.
    • Dtsch Med Wochenschr. 2020 Oct;145(20):1460-1463. German. doi: 10.1055/a-1026-3620. Epub 2020 Oct 6.
    • Review, [Article in German]
    • Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer.
    • Dülgar Ö, Ilvan S, Turna ZH.
    • Eur J Breast Health. 2020 Apr 17 [eCollection 2020 Oct];16(4):276-281. doi: 10.5152/ejbh.2020.5305.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC.
    • Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
    • Guideline: FDA issues alert on a drug combination to treat triple-negative breast cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Sep 18.

    Related:

    FDA Release: FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer (U.S. Food & Drug Administration)

    • The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
    • Huynh MM, Pambid MR, Jayanthan A, Dorr A, Los G, Dunn SE.
    • Expert Opin Investig Drugs. 2020 Sep 1. doi: 10.1080/13543784.2020.1818067. Epub ahead of print.
    • Review
    • Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    • Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom PJ, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH.
    • Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Epub ahead of print.
    • Management of early breast cancer in patients bearing germline BRCA mutations.
    • t'Kint de Roodenbeke MD, Pondé N, Buisseret L, Piccart M.
    • Semin Oncol. 2020 Aug 18:S0093-7754(20)30083-X. doi: 10.1053/j.seminoncol.2020.07.006. Epub ahead of print.
    • Review
    • Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    • Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.
    • TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
    • Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP.
    • Ann Oncol. 2020 Aug 13:S0923-7534(20)42061-7. doi: 10.1016/j.annonc.2020.08.2064. Epub ahead of print.
    • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    • Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM.
    • JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.2965. Epub ahead of print.
    • AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
    • Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM.
    • Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
    • Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    • Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234. Epub ahead of print.
    • Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
    • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.
    • Nat Commun. 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2.
    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • Current and Emerging Biologic Therapies for Triple Negative Breast Cancer.
    • Shaikh SS, Emens LA.
    • Expert Opin Biol Ther. 2020 Jul 25. doi: 10.1080/14712598.2020.1801627. Epub ahead of print.
    • Review
    • Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    • Go A, Jang JW, Lee W, Ha JD, Kim HJ, Nam HJ.
    • Eur J Med Chem. 2020 Jul 19;204:112635. doi: 10.1016/j.ejmech.2020.112635. Epub ahead of print.
    • Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.
    • Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, Willis NA, Chen CH, Taveira MO, Zhou XZ, Lu KP, Scully R, Wulf GM, Hu H.
    • Cancer Res. 2020 Jul 15;80(14):3033-3045. doi: 10.1158/0008-5472.CAN-19-2739. Epub 2020 Mar 19.

    Related:

    Commentary:

    A Novel Mechanism to Induce BRCAness in Cancer Cells.

    • Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
    • González-Martínez S, Pérez-Mies B, Carretero-Barrio I, Palacios-Berraquero ML, Perez-García J, Cortés J, Palacios J.
    • Cancers (Basel). 2020 Jul 8;12(7):E1832. doi: 10.3390/cancers12071832.
    • Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    • Luo S, Zhang Y, Yang Y, Zhu S, Liu W, Zhu J, Liang X, Jiang Z, Sun S, Hou X, Xiao Y, Li X.
    • Gynecol Oncol. 2020 Jul;158(1):66-76. doi: 10.1016/j.ygyno.2020.04.695. Epub 2020 May 8.
    • Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
    • Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, Laurentiis M.
    • Int J Mol Sci. 2020 Jun 27;21(13):E4579. doi: 10.3390/ijms21134579.
    • NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
    • Miao K, Lei JH, Valecha MV, Zhang A, Xu J, Wang L, Lyu X, Chen S, Miao Z, Zhang X, Su SM, Shao F, Rajendran BK, Bao J, Zeng J, Sun H, Chen P, Tan K, Chen Q, Wong KH, Xu X, Deng CX.
    • Nat Commun. 2020 Jun 26;11(1):3256. doi: 10.1038/s41467-020-16936-9.
    • Metastatic triple-negative breast cancer: Established and emerging treatments.
    • Puri A, Reddy TP, Patel TA, Chang JC.
    • Breast J. 2020 Jun 23. doi: 10.1111/tbj.13946. Epub ahead of print.
    • Review
    • Triple-negative breast cancer molecular subtyping and treatment progress.
    • Yin L, Duan JJ, Bian XW, Yu SC.
    • Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
    • A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
    • Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM.
    • Oncologist. 2020 Jun 8. doi: 10.1634/theoncologist.2020-0491. Epub ahead of print.
    • Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig? [Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?].
    • Schmidt M.
    • J Gynakol Endokrinol. 2020 Jun 2:1-3. German. doi: 10.1007/s41974-020-00141-z. Epub ahead of print.
    • Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
    • Lee JS, Yost SE, Yuan Y.
    • Cancers (Basel). 2020 May 29;12(6):E1404. doi: 10.3390/cancers12061404.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • The evolving management of metastatic triple negative breast cancer.
    • Malhotra MK, Emens LA.
    • Semin Oncol. 2020 May 28:S0093-7754(20)30044-0. doi: 10.1053/j.seminoncol.2020.05.005.
    • Review
    • Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
    • Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B.
    • Oncologist. 2020 May 26. doi: 10.1634/theoncologist.2020-0039. Epub ahead of print.
    • Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    • Ma D, Jiang YZ, Xiao Y, Xie MD, Zhao S, Jin X, Xu XE, Shao ZM.
    • Cancer. 2020 May 8. doi: 10.1002/cncr.32922. [Epub ahead of print]
    • BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    • Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.
    • Breast Cancer Res Treat. 2020 Apr 20. doi: 10.1007/s10549-020-05647-w. [Epub ahead of print]
    • Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    • Lin PH, Chen M, Tsai LW, Lo C, Yen TC, Huang TY, Chen CK, Fan SC, Kuo SH, Huang CS.
    • Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.
    • Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
    • Wang N, Li K, Huang W, Kong W, Liu X, Shi W, Xie F, Jiang H, Song G, Di L, Wang Q, Yu J, Li H.
    • Chin J Cancer Res. 2020 Apr;32(2):149-162. doi: 10.21147/j.issn.1000-9604.2020.02.03.
    • BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S.
    • Cancers (Basel). 2020 Mar 30;12(4). pii: E828. doi: 10.3390/cancers12040828.
    • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    • Keung MY, Wu Y, Badar F, Vadgama JV.
    • J Clin Med. 2020 Mar 30;9(4). pii: E940. doi: 10.3390/jcm9040940.
    • Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
    • Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Schneeweiss A, Hahnen E.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0007. [Epub ahead of print]
    • Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.
    • Knowlson C, Haddock P, Bingham V, McQuaid S, Mullan PB, Buckley NE.
    • Ther Adv Med Oncol. 2020 Mar 9;12:1758835920906047. doi: 10.1177/1758835920906047. eCollection 2020.
    • Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
    • García IA, Garro C, Fernandez E, Soria G.
    • Mutat Res. 2020 Feb 25;821:111693. doi: 10.1016/j.mrfmmm.2020.111693. [Epub ahead of print]
    • Review
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
    • BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
    • Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S.
    • Diagnostics (Basel). 2020 Feb 21;10(2). pii: E119. doi: 10.3390/diagnostics10020119.
    • Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    • Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    • J Surg Res. 2020 Feb 21;250:200-208. doi: 10.1016/j.jss.2019.12.040. [Epub ahead of print]
    • Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
    • Kaplan HG, Calip GS, Malmgren JA.
    • Oncologist. 2020 Feb 19. doi: 10.1634/theoncologist.2019-0099. [Epub ahead of print]
    • BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    • Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E.
    • Sci Transl Med. 2020 Feb 19;12(531). pii: eaax2625. doi: 10.1126/scitranslmed.aax2625.
    • Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    • Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L.
    • Expert Opin Pharmacother. 2020 Feb 13:1-13. doi: 10.1080/14656566.2020.1724957. [Epub ahead of print]
    • Review
    • Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
    • Teraoka S, Sato E, Narui K, Yamada A, Fujita T, Yamada K, Oba M, Ishikawa T.
    • J Surg Res. 2020 Feb 7;250:143-147. doi: 10.1016/j.jss.2019.12.047. [Epub ahead of print]
    • BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.
    • Tazzite A, Jouhadi H, Benider A, Nadifi S.
    • Curr Drug Targets. 2020 Feb 3. doi: 10.2174/1389450121666200203162541. [Epub ahead of print]
    • Review
    • International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
    • Thomssen C, Lüftner D, Untch M, Haidinger R, Würstlein R, Harbeck N, Augustin D, Briest S, Ettl J, Fasching PA, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Perlova-Griff L, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K.
    • Breast Care (Basel). 2020 Feb;15(1):82-95. doi: 10.1159/000505957. Epub 2020 Feb 10.
    • Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
    • Pogoda K, Niwinska A, Sarnowska E, Nowakowska D, Jagiello-Gruszfeld A, Siedlecki J, Nowecki Z.
    • J Oncol. 2020 Jan 27;2020:8545643. doi: 10.1155/2020/8545643. eCollection 2020.
    • Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
    • Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE Jr, Sikov WM, Untch M.
    • JAMA Surg. 2020 Jan 8:e195410. doi: 10.1001/jamasurg.2019.5410. [Epub ahead of print]
    • Microsatellite instability in Japanese female patients with triple-negative breast cancer.
    • Kurata K, Kubo M, Kai M, Mori H, Kawaji H, Kaneshiro K, Yamada M, Nishimura R, Osako T, Arima N, Okido M, Oda Y, Nakamura M.
    • Breast Cancer. 2020 Jan 6. doi: 10.1007/s12282-019-01043-5. [Epub ahead of print]
    • The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition.
    • Yusoh NA, Leong SW, Chia SL, Harun SN, Abdul Rahman MB, Vallis KA, Gill MR, Ahmad H.
    • ACS Chem Biol. 2020 Jan 3. doi: 10.1021/acschembio.9b00843. [Epub ahead of print]
    • BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab.
    • Lin J, Yang X, Zhao H.
    • JAMA Oncol. 2019 Dec 26. doi: 10.1001/jamaoncol.2019.4595. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply.

    Original research:

    Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

    Original research:

    Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

    • Triple negative breast cancer: A thorough review of biomarkers.
    • da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC.
    • Crit Rev Oncol Hematol. 2019 Dec 20;145:102855. doi: 10.1016/j.critrevonc.2019.102855. [Epub ahead of print]
    • Immunotherapy Regimens Yield Contrasting Results in Early Triple Negative Breast Cancer.
    • Ashford M.
    • GenomeWeb. 2019 Dec 12.
    • Research news, Conference report
    • Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
    • Park HS, Lee JD, Kim JY, Park S, Kim JH, Han HJ, Choi YA, Choi AR, Sohn JH, Kim SI.
    • PLoS One. 2019 Dec 10;14(12):e0225082. doi: 10.1371/journal.pone.0225082. eCollection 2019.
    • Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
    • Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.
    • Clin Cancer Res. 2019 Dec 3. pii: clincanres.0664.2019. doi: 10.1158/1078-0432.CCR-19-0664. [Epub ahead of print]
    • Targeted Therapies for Triple-Negative Breast Cancer.
    • Lyons TG.
    • Curr Treat Options Oncol. 2019 Nov 21;20(11):82. doi: 10.1007/s11864-019-0682-x.
    • Review
    • Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
    • Fitzpatrick A, Tutt A.
    • Ther Adv Med Oncol. 2019 Nov 1;11:1758835919882581. doi: 10.1177/1758835919882581. eCollection 2019.
    • RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    • Haynes B, Gajan A, Nangia-Makker P, Shekhar MP.
    • Biochim Biophys Acta Mol Basis Dis. 2019 Oct 19:165561. doi: 10.1016/j.bbadis.2019.165561. [Epub ahead of print]
    • Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer.
    • Guney Eskiler G, Sahin E, Deveci Ozkan A, Cilingir Kaya OT, Kaleli S.
    • Nutr Cancer. 2019 Oct 1:1-10. doi: 10.1080/01635581.2019.1670216. [Epub ahead of print]
    • Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
    • Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.
    • Nat Med. 2019 Sep 30. doi: 10.1038/s41591-019-0582-4. [Epub ahead of print]
    • Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    • Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K.
    • Breast Cancer Res. 2019 Sep 6;21(1):104. doi: 10.1186/s13058-019-1192-2.
    • PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
    • Beck C, Rodriguez-Vargas JM, Boehler C, Robert I, Heyer V, Hanini N, Gauthier LR, Tissier A, Schreiber V, Elofsson M, Reina San Martin B, Dantzer F.
    • Cell Death Differ. 2019 Sep;26(9):1615-1630. doi: 10.1038/s41418-018-0233-1. Epub 2018 Nov 15.
    • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
    • Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.
    • Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]
    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
    • Kundur S, Prayag A, Selvakumar P, Nguyen H, McKee L, Cruz C, Srinivasan A, Shoyele S, Lakshmikuttyamma A.
    • J Cell Physiol. 2019 Jul;234(7):11103-11118. doi: 10.1002/jcp.27761. Epub 2018 Nov 27.
    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    • Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

    Related:

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.
    • Pascual T, Gonzalez-Farre B, Teixidó C, Oleaga L, Oses G, Ganau S, Chic N, Riu G, Adamo B, Galván P, Vidal M, Soy D, Urbano Á, Muñoz M, Prat A.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 7];3:1-6. doi: 10.1200/PO.19.00012.
    • [Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.]
    • Palácová M.
    • Klin Onkol. 2019 Summer;32(Supplementum2):24-30. doi: 10.14735/amko2019S24.
    • [Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.]
    • Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.
    • Homologous recombination deficiency in triple negative breast cancer.
    • Belli C, Duso BA, Ferraro E, Curigliano G.
    • Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.
    • Review
    • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
    • Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ.
    • Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
    • Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.
    • Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW.
    • Breast Cancer Res Treat. 2019 May 22. doi: 10.1007/s10549-019-05264-2. [Epub ahead of print]
    • How I treat metastatic triple-negative breast cancer.
    • Caparica R, Lambertini M, de Azambuja E.
    • ESMO Open. 2019 May 13;4(Suppl 2):e000504. doi: 10.1136/esmoopen-2019-000504. eCollection 2019.
    • Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    • Garber HR, Litton JK.
    • Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.
    • Review
    • BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
    • DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    • Shi Y, Jin J, Wang X, Ji W, Guan X.
    • Neoplasia. 2019 Apr 24;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. [Epub ahead of print]
    • PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer.
    • Pantelidou C, Sonzogni O, de Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.
    • Cancer Discov. 2019 Apr 23. pii: CD-18-1218. doi: 10.1158/2159-8290.CD-18-1218. [Epub ahead of print]
    • Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
    • Na B, Yu X, Withers T, Gilleran J, Yao M, Foo TK, Chen C, Moore D, Lin Y, Kimball SD, Xia B, Ganesan S, Carpizo DR.
    • NPJ Breast Cancer. 2019 Apr 15;5:14. doi: 10.1038/s41523-019-0110-1. eCollection 2019.
    • Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    • Imanishi S, Naoi Y, Shimazu K, Shimoda M, Kagara N, Tanei T, Miyake T, Kim SJ, Noguchi S.
    • Breast Cancer Res Treat. 2019 Apr;174(3):627-637. doi: 10.1007/s10549-018-05120-9. Epub 2019 Jan 3.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Related:

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
    • Force J, Leal JHS, McArthur HL.
    • Curr Treat Options Oncol. 2019 Mar 28;20(4):35. doi: 10.1007/s11864-019-0634-5.
    • Review
    • The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2019 Mar 25;17:11. doi: 10.1186/s13053-019-0111-y. eCollection 2019.
    • Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    • Sang M, Meng L, Ma C, Liu S, Sang M, Chang S, Liu F, Lian Y, Geng C.
    • Biomed Pharmacother. 2019 Mar;111:169-177. doi: 10.1016/j.biopha.2018.11.136. Epub 2018 Dec 21.
    • A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    • Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.
    • Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.
    • Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
    • Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J.
    • Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • A new paradox for pCR in BRCA mutation carriers.
    • Rounis K, Mavroudis D.
    • Transl Cancer Res. 2019 Mar;8(Suppl 2):S99-S102. doi: 10.21037/tcr.2018.10.25.

    Related:

    Original research:

    BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

    • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.
    • N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

    Related:

    Research news: Smart drug shows promising results for treatment of metastatic triple-negative breast cancer. (FORCE. XRAYS.)

    • BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    • Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    • Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
    • Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    • Tian T, Shan L, Yang W, Zhou X, Shui R.
    • Hum Pathol. 2019 Feb;84:231-238. doi: 10.1016/j.humpath.2018.10.004. Epub 2018 Oct 16.
    • Triple-negative breast cancer: the reality in Chile and in Latin America.
    • Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M.
    • Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019.
    • The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    • Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.
    • Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
    • PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
    • Matthews Hew T, Zuberi L.
    • J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619864989. doi: 10.1177/2324709619864989.
    • A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
    • Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y.
    • Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    • Fremd C, Jaeger D, Schneeweiss A.
    • Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
    • Review
    • Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    • Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.
    • Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.
    • BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
    • Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL.
    • Am J Clin Oncol. 2018 Dec;41(12):1252-1256. doi: 10.1097/COC.0000000000000466.
    • Talazoparib: First Global Approval.
    • Hoy SM.
    • Drugs. 2018 Dec;78(18):1939-1946. doi: 10.1007/s40265-018-1026-z.
    • Review
    • [Systemic Treatment of Early and Metastatic Breast Cancer.]
    • Fehm T, Müller V.
    • Dtsch Med Wochenschr. 2018 Dec;143(24):1751-1754. doi: 10.1055/a-0638-4231. Epub 2018 Dec 3.
    • Review, [Article in German]
    • Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
    • Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, Polin LA, Gupta S, Mao G, Shekhar MP.
    • Mol Cancer Ther. 2018 Dec;17(12):2586-2597. doi: 10.1158/1535-7163.MCT-18-0364. Epub 2018 Sep 21.
    • Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    • Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S.
    • Bioconjug Chem. 2018 Nov 21;29(11):3817-3832. doi: 10.1021/acs.bioconjchem.8b00667. Epub 2018 Oct 25.
    • Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT).
    • Principal Investigator: Sharma P.
    • ClinicalTrials.gov. Last Update Posted: 2018 Oct 11. First Posted: 2014 Nov 27.
    • Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer.
    • De La Cruz LM, Czerniecki BJ.
    • Ann Surg Oncol. 2018 Oct;25(10):2852-2857. doi: 10.1245/s10434-018-6620-5. Epub 2018 Jul 16.
    • Genetic Markers in Triple-Negative Breast Cancer.
    • Sporikova Z, Koudelakova V, Trojanec R, Hajduch M.
    • Clin Breast Cancer. 2018 Oct;18(5):e841-e850. doi: 10.1016/j.clbc.2018.07.023. Epub 2018 Aug 4.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
    • Le D, Gelmon KA.
    • Expert Rev Clin Pharmacol. 2018 Sep;11(9):833-839. doi: 10.1080/17512433.2018.1513321. Epub 2018 Aug 30.
    • Review
    • A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status.
    • Su YW, Hung CY, Lam HB, Chang YC, Yang PS.
    • Clin Med Insights Oncol. 2018 Aug 21;12:1179554918794672. doi: 10.1177/1179554918794672. eCollection 2018.
    • Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
    • Diana A, Franzese E, Centonze S, Carlino F, Corte CMD, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M.
    • Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6.
    • Review
    • Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    • Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, Wu J, Shao ZM, Yang WT, Hu XC.
    • Ann Oncol. 2018 Aug 1;29(8):1741-1747. doi: 10.1093/annonc/mdy209.
    • BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
    • Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.
    • J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.

    Related:

    Commentary:

    A new paradox for pCR in BRCA mutation carriers.

    • Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.
    • Battisti NML, Okonji D, Manickavasagar T, Mohammed K, Allen M, Ring A.
    • Breast. 2018 Aug;40:60-66. doi: 10.1016/j.breast.2018.04.014. Epub 2018 Apr 23.
    • Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    • Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP.
    • Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22.
    • Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
      • Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP.
    • Breast Cancer Res Treat. 2018 Aug;171(1):21-31. doi: 10.1007/s10549-018-4807-x. Epub 2018 May 7.
    • Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer.
    • Dunne M, Dou YN, Drake DM, Spence T, Gontijo SML, Wells PG, Allen C.
    • J Control Release. 2018 Jul 28;282:35-45. doi: 10.1016/j.jconrel.2018.04.029. Epub 2018 Apr 16.
    • Therapeutic landscape in mutational triple negative breast cancer.
    • Shi Y, Jin J, Ji W, Guan X.
    • Mol Cancer. 2018 Jul 14;17(1):99. doi: 10.1186/s12943-018-0850-9.
    • Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    • Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M.
    • Ann Oncol. 2018 Jul 1;29(7):1497-1508. doi: 10.1093/annonc/mdy127.
    • Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    • Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B.
    • Breast Cancer Res Treat. 2018 Jul;170(1):101-109. doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.
    • Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    • Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W.
    • Br J Cancer. 2018 Jul;119(1):76-79. doi: 10.1038/s41416-018-0142-6. Epub 2018 Jun 8.
    • Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    • Wang X, Shi Y, Huang D, Guan X.
    • Cancer Treat Rev. 2018 Jul;68:62-68. doi: 10.1016/j.ctrv.2018.05.014. Epub 2018 May 31.
    • Review
    • Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    • Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.
    • Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.
    • The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
    • Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, Cona MS, Maggi C, Ferrari B, Manoukian S, Mariani G, Bianchi G, Capri G, Rivoltini L, de Braud F.
    • Sci Rep. 2018 Jun 7;8(1):8703. doi: 10.1038/s41598-018-27075-z.
    • Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    • Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.
    • Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.
    • Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    • Al-Subhi N, Ali R, Abdel-Fatah T, Moseley PM, Chan SYT, Green AR, Ellis IO, Rakha EA, Madhusudan S.
    • Breast Cancer Res Treat. 2018 Jun;169(2):277-286. doi: 10.1007/s10549-018-4683-4. Epub 2018 Feb 2.
    • First international TNBC conference meeting report.
    • Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.
    • Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.
    • Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    • Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.
    • Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.
    • The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    • Papadimitriou M, Mountzios G, Papadimitriou CA.
    • Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.
    • Review
    • Advances in the systemic treatment of triple-negative breast cancer.
    • Lebert JM, Lester R, Powell E, Seal M, McCarthy J.
    • Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150. doi: 10.3747/co.25.3954. Epub 2018 Jun 13.
    • Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
    • Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):65-77. doi: 10.1200/EDBK_200715.
    • Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    • Kwa MJ, Adams S.
    • Cancer. 2018 May 15;124(10):2086-2103. doi: 10.1002/cncr.31272. Epub 2018 Feb 9.
    • Review
    • Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.
    • Luo L, Gao W, Wang J, Wang D, Peng X, Jia Z, Jiang Y, Li G, Tang D, Wang Y.
    • Med Sci Monit. 2018 May 15;24:3176-3183. doi: 10.12659/MSM.907256.
    • How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
    • Park JH, Ahn JH, Kim SB.
    • ESMO Open. 2018 May 3;3(Suppl 1):e000357. doi: 10.1136/esmoopen-2018-000357. eCollection 2018.
    • Triple negative breast cancer: new therapeutic approaches and BRCA status.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • APMIS. 2018 May;126(5):371-379. doi: 10.1111/apm.12836.
    • Review
    • 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.
    • Untch M, Würstlein R, Marschner N, Lüftner D, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Harbeck N, Thomssen C.
    • Geburtshilfe Frauenheilkd. 2018 May;78(5):469-480. doi: 10.1055/a-0594-2243. Epub 2018 Jun 4.
    • Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney.
    • Naher S, Tognela A, Moylan E, Adams DH, Kiely BE.
    • Intern Med J. 2018 May;48(5):567-572. doi: 10.1111/imj.13628.
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder S, Bliss JM.v
    • Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
    • SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Xu L, Che X, Wu Y, Song N, Shi S, Wang S, Li C, Zhang L, Zhang X, Qu X, Teng Y.
    • Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
    • LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.
    • Maubant S, Tahtouh T, Brisson A, Maire V, Némati F, Tesson B, Ye M, Rigaill G, Noizet M, Dumont A, Gentien D, Marty-Prouvost B, de Koning L, Mahmood SF, Decaudin D, Cruzalegui F, Tucker GC, Roman-Roman S, Dubois T.
    • Oncotarget. 2018 Apr 27;9(32):22586-22604. doi: 10.18632/oncotarget.25187. eCollection 2018 Apr 27.
    • Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
    • Ren D, Zhu X, Kong R, Zhao Z, Sheng J, Wang J, Xu X, Liu J, Cui K, Zhang XH, Zhao H, Wong STC.
    • Cancer Res. 2018 Apr 15;78(8):2052-2064. doi: 10.1158/0008-5472.CAN-17-2994. Epub 2018 Mar 22.
    • Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    • Sharma P.
    • Curr Treat Options Oncol. 2018 Apr 14;19(5):22. doi: 10.1007/s11864-018-0539-8.
    • Review
    • Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    • Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ.
    • Am J Cancer Res. 2019 Apr 1;9(4):800-815. eCollection 2019.
    • Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    • Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C.
    • Ann Oncol. 2018 Apr 1;29(4):895-902. doi: 10.1093/annonc/mdy024.
    • Practical consensus recommendations on management of triple-negative metastatic breast cancer.
    • Rangarao R, Smruti BK, Singh K, Gupta A, Batra S, Choudhary RK, Gupta A, Sahani S, Kabra V, Parikh PM, Aggarwal S.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):127-131. doi: 10.4103/sajc.sajc_118_18.
    • Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer.
    • Bhattacharyya GS, Walia M, Nandi M, Murli A, Salim S, Rajpurohit S, Shinde S, Aggarwal S, Parikh PM.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):156-158. doi: 10.4103/sajc.sajc_126_18.
    • Genetic alterations in sporadic triple negative breast cancer.
    • Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I.
    • Breast. 2018 Apr;38:30-38. doi: 10.1016/j.breast.2017.11.006. Epub 2017 Dec 5.
    • Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    • Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.
    • Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.
    • PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    • Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM.
    • Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4.
    • Review
    • Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    • Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR.
    • J Am Coll Surg. 2018 Apr;226(4):560-565. doi: 10.1016/j.jamcollsurg.2017.12.037. Epub 2018 Jan 31.
    • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.
    • Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.
    • Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
    • Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.
    • J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.
    • Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    • Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF.
    • Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821.
    • Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    • Dávila-González D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.
    • Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi: 10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4.
    • Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    • Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    • Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
    • Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.
    • Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.
    • Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4.
    • p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
    • Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B.
    • Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.
    • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.
    • Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111-6. doi: 10.1016/S1470-2045(18)30111-6. [Epub ahead of print]
    • Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    • Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.
    • J Clin Oncol. 2018 Feb 20;36(6):543-553. doi: 10.1200/JCO.2017.76.0033. Epub 2018 Jan 3.

    Related:

    Editorial:

    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.

    • Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.
    • Tayyari F, Gowda GAN, Olopade OF, Berg R, Yang HH, Lee MP, Ngwa WF, Mittal SK, Raftery D, Mohammed SI.
    • Oncotarget. 2018 Feb 7;9(14):11677-11690. doi: 10.18632/oncotarget.24433. eCollection 2018 Feb 20.
    • Survival and mutation status in breast cancer patients under age 40.
    • [No author given]
    • FORCE. XRAYS. 2018 Feb 15.

    Related:

    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    • Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    • Al-Subhi N, Ali R, Abdel-Fatah T, Moseley RM, Chan SYT, Green AR, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2018 Feb 2. doi: 10.1007/s10549-018-4683-4. [Epub ahead of print]
    • Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    • Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.
    • Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.
    • BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    • Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    • Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    • Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.
    • Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.

    Related:

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    Research news:

    Young women with BRCA mutation can safely postpone radical surgery.

    Press: Survival After Breast Cancer 'Unaffected by BRCA Status' (Medscape)

    Research news: Survival and mutation status in breast cancer patients under age 40. (FORCE: XRAYS)

    • Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
    • Echavarría I, López-Tarruella S, Picornell AC, Garcia-Saenz JA, Jerez-Gilarranz Y, Hoadley KA, Gomez H, Moreno F, Del Monte-Millán M, Marquez-Rodas I, Alvarez EL, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martín M.
    • Clin Cancer Res. 2018 Jan 29. pii: clincanres.1912.2017. doi: 10.1158/1078-0432.CCR-17-1912. [Epub ahead of print]
    • Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
    • Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F.
    • Cancer Manag Res. 2018 Jan 15;10:91-103. doi: 10.2147/CMAR.S146658. eCollection 2018.
    • TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    • Byrd TT, Fousek K, Pignata A, Szot C5, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N.
    • Cancer Res. 2018 Jan 15;78(2):489-500. doi: 10.1158/0008-5472.CAN-16-1911. Epub 2017 Nov 28.
    • Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    • Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.
    • J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033. [Epub ahead of print]

    Related:

    Editorial:

    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.

    • OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer.
    • Chiu HW, Lin HY, Tseng IJ, Lin YF.
    • Oncotarget. 2017 Dec 9;9(1):553-565. doi: 10.18632/oncotarget.23074. eCollection 2018 Jan 2.
    • MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    • Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D.
    • Cancer Res. 2018 Jan 1;78(1):205-215. doi: 10.1158/0008-5472.CAN-17-1636. Epub 2017 Dec 20.
    • Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
    • Privat M, Rudewicz J, Sonnier N, Tamisier C, Ponelle-Chachuat F, Bignon YJ.
    • Int J Med Sci. 2018 Jan 1;15(1):46-58. doi: 10.7150/ijms.20508. eCollection 2018.
    • Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer.
    • Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, Xie X, Xiao X.
    • Biomed Pharmacother. 2018 Jan;97:1275-1281. doi: 10.1016/j.biopha.2017.11.055. Epub 2017 Dec 14.
    • Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    • Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP.
    • Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14.
    • Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    • Reddy SM, Barcenas CH, Sinha AK, Hsu , Moulder , Tripathy D, Hortobagyi GN, Valero V.
    • Br J Cancer. 2018 Jan;118(1):17-23. doi: 10.1038/bjc.2017.379. Epub 2017 Dec 12.
    • Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    • Lee A, Djamgoz MBA.
    • Cancer Treat Rev. 2018 Jan;62:110-122. doi: 10.1016/j.ctrv.2017.11.003. Epub 2017 Nov 13.
    • Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
    • Ozretic P, Alvir I, Sarcevic B, Vujaskovic Z, Rendic-Miocevic Z, Roguljic A, Beketic-Oreskovic L.
    • Int J Biol Markers. 2018 Jan;33(1):109-115. doi: 10.5301/ijbm.5000291.
    • Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
    • Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF; kConFab Investigators.
    • Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.
    • BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    • Okuma HS, Yonemori K.
    • Adv Exp Med Biol. 2017 [2017 Dec 28];1026:271-286. doi: 10.1007/978-981-10-6020-5_13.
    • Review
    • HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
    • Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN.
    • Oncotarget. 2017 Dec 12;8(69):114156-114172. doi: 10.18632/oncotarget.23169. eCollection 2017 Dec 26.
    • The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer.
    • Biswas T, Efird JT, Prasad S, Jindal C, Walker PR.
    • Oncotarget. 2017 Nov 20;8(68):112712-112719. doi: 10.18632/oncotarget.22521. eCollection 2017 Dec 22.
    • miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    • Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ.
    • Breast Cancer Res. 2017 Dec 19;19(1):133. doi: 10.1186/s13058-017-0918-2.
    • Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers.
    • Kozin SV, Maimon N, Wang R, Gupta N, Munn L, Jain RK, Garkavtsev I.
    • Oncotarget. 2017 Nov 26;8(65):108292-108302. doi: 10.18632/oncotarget.22660. eCollection 2017 Dec 12.
    • Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis.
    • Deng L, Lei Q, Wang Y, Wang Z, Xie G, Zhong X, Wang Y, Chen N, Qiu Y, Pu T, Bu H, Zheng H.
    • Oncotarget. 2017 Oct 6;8(65):108712-108725. doi: 10.18632/oncotarget.21561. eCollection 2017 Dec 12.
    • MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    • Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, Wang GY.
    • Cancer Res. 2017 Dec 1;77(23):6641-6650. doi: 10.1158/0008-5472.CAN-16-3452. Epub 2017 Sep 26.
    • Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    • Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L.
    • JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.
    • The Role of the Androgen Receptor Signaling in Breast Malignancies.
    • Christopoulos PF, Vlachogiannis NI, Vogkou CT, Koutsilieris M.
    • Anticancer Res. 2017 Dec;37(12):6533-6540.
    • BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
    • van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.
    • Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.
    • New agents for the management of resistant metastatic breast cancer.
    • Anampa J, Sparano JA.
    • Expert Opin Pharmacother. 2017 Dec;18(17):1815-1831. doi: 10.1080/14656566.2017.1409206. Epub 2017 Nov 27.
    • Review
    • A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.
    • Ryan D, Bogan D, Davies J, Koziol J, ElShamy WM.
    • Oncotarget. 2017 Sep 14;8(61):103182-103206. doi: 10.18632/oncotarget.20892. eCollection 2017 Nov 28.
    • Antitumor Activity of Copper (I)-Nicotinate Complex and Autophagy Modulation in HCC1806 Breast Cancer Cells.
    • Abdel-Mohsen MA, El-Shafey ES, Malak CA, Abou-Yossef MM.
    • Anticancer Agents Med Chem. 2017 Nov 24;17(11):1526-1536. doi: 10.2174/1871520617666170327144122.
    • Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
    • Teo ZL, Versaci S, Dushyanthen S, Caramia F, Savas P, Mintoff C, Zethoven M, Virassamy B, Luen SJ, McArthur GA, Phillips WA, Darcy PK, Loi S.
    • Cancer Res. 2017 Nov 15;77(22):6340-6352. doi: 10.1158/0008-5472.CAN-17-2210. Epub 2017 Sep 25.
    • Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    • Garber J.
    • OncoTherapy Network. 2017 Nov 15.
    • Role of Platinum in Early-Stage Triple-Negative Breast Cancer.
    • La Belle A, Khatib J, Schiemann WP, Vinayak S.
    • Curr Treat Options Oncol. 2017 Nov 6;18(11):68. doi: 10.1007/s11864-017-0506-9.
    • Review
    • Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    • Lanz HL, Saleh A, Kramer B, Cairns J, Ng CP, Yu J, Trietsch SJ, Hankemeier T, Joore J, Vulto P, Weinshilboum R, Wang L.
    • BMC Cancer. 2017 Nov 2;17(1):709. doi: 10.1186/s12885-017-3709-3.
    • Tumor Infiltrating Lymphocytes May be Predictive in African-American Women with Triple-Negative Breast Cancer.
    • Schieszer J.
    • OncoTherapy Network. 2017 Nov 2.
    • A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    • Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.
    • Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.
    • Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    • Speyer CL, Bukhsh MA, Jafry WS, Sexton RE, Bandyopadhyay S, Gorski DH.
    • Breast Cancer Res Treat. 2017 Nov;166(2):407-419. doi: 10.1007/s10549-017-4435-x. Epub 2017 Aug 5.
    • A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy.
    • Shi M, Ma F, Liu J, Xing H, Zhu H, Yu J, Yang M.
    • Breast Cancer Res Treat. 2017 Nov;166(1):109-116. doi: 10.1007/s10549-017-4395-1. Epub 2017 Jul 25.
    • A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
    • Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J.
    • Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
    • The role of BRCA status on prognosis in patients with triple-negative breast cancer.
    • Xie Y, Gou Q, Wang Q, Zhong X, Zheng H.
    • Oncotarget. 2017 Aug 3;8(50):87151-87162. doi: 10.18632/oncotarget.19895. eCollection 2017 Oct 20.
    • Role of PARP Inhibitors in Triple-Negative Breast Cancer.
    • Azvolinsky A, Garber J.
    • OncoTherapy Network. 2017 Oct 4.
    • Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
    • Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.
    • Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.
    • Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.
    • Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA.
    • Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14.
    • Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    • Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.
    • JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.

    Related:

    Editorial:

    Use of Neoadjuvant Platinum-The Ongoing Conundrum.

    • PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells).
    • Meena R, Kumar S, Kumar R, Gaharwar US, Rajamani P.
    • Biomed Pharmacother. 2017 Oct;94:944-954. doi: 10.1016/j.biopha.2017.07.151. Epub 2017 Aug 12.
    • Rational combination of immunotherapy for triple negative breast cancer treatment.
    • Li CW, Lim SO, Hsu JL, Hung MC.
    • Chin Clin Oncol. 2017 Oct;6(5):54. doi: :10.21037/cco.2017.08.04.

    Related:

    Free Medscape-style version: Rational Combination of Immunotherapy for Triple Negative Breast Cancer Treatment (Medscape)

    • miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
    • Fkih M'hamed I, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ, Kenani A.
    • Pathol Oncol Res. 2017 Oct;23(4):815-827. doi: 10.1007/s12253-017-0188-4. Epub 2017 Jan 18.
    • Contralateral Prophylactic Mastectomy.
    • Ramaswami R, Morrow M, Jagsi R.
    • N Engl J Med. 2017 Sep 28;377(13):1288-1291. doi: 10.1056/NEJMclde1708293.
    • Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
    • Jeong HM, Kim RN, Kwon MJ, Oh E, Han J, Lee SK, Choi JS, Park S, Nam SJ, Gong GY, Nam JW, Choi DH, Lee H, Nam BH, Choi YL, Shin YK.
    • Oncotarget. 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.
    • Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    • Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.
    • Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.
    • Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    • Klimov S, Rida PC, Aleskandarany MA, Green AR, Ellis IO, Janssen EA, Rakha EA, Aneja R.
    • Br J Cancer. 2017 Sep 5;117(6):826-834. doi: 10.1038/bjc.2017.224. Epub 2017 Jul 18.
    • Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer.
    • Saleh SMI, Bertos N, Gruosso T, Gigoux M, Souleimanova M, Zhao H, Omeroglu A, Hallett MT, Park M.
    • Cancer Res. 2017 Sep 1;77(17):4673-4683. doi: 10.1158/0008-5472.CAN-16-3427. Epub 2017 Jun 26.
    • The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    • Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.
    • Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.
    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.
    • Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY.
    • NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017.
    • Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    • Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F.
    • Breast Cancer Res. 2017 Aug 15;19(1):93. doi: 10.1186/s13058-017-0878-6.
    • Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component.
    • Avigdor BE, Beierl K, Gocke CD, Zabransky DJ, Cravero K, Kyker-Snowman K, Button B, Chu D, Croessmann S, Cochran RL, Connolly RM, Park BH, Wheelan SJ, Cimino-Mathews A.
    • Clin Cancer Res. 2017 Aug 15;23(16):4875-4884. doi: 10.1158/1078-0432.CCR-17-0108. Epub 2017 Apr 19.
    • H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
    • Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli A, Ciuffreda P, Prosperi D, Corsi F.
    • Sci Rep. 2017 Aug 8;7(1):7505. doi: 10.1038/s41598-017-07617-7.
    • Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.
    • Bhatti S, Heldstab J, Lehn C, Tawfik O, Ash RM, Hout DR, Seitz RS, Bailey DB, O’Dea AP, Jensen RA, Fan F, Khan QJ, Godwin AK, Sharma P.
    • JCO Precis Oncol. doi: 10.1200/PO.17.00032. Epub 2017 Aug 7.
    • Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
    • Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.
    • Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.
    • Identification of new tumor suppressor genes in triple-negative breast cancer.
    • Rangel R, Guzman-Rojas L, Kodama T, Kodama M, Newberg JY, Copeland NG, Jenkins NA.
    • Cancer Res. 2017 Aug 1;77(15):4089-4101. doi: 10.1158/0008-5472.CAN-17-0785. Epub 2017 Jul 19.
    • Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    • Harbeck N, Gluz O.
    • Breast. 2017 Aug;34 Suppl 1:S99-S103. doi: 10.1016/j.breast.2017.06.038. Epub 2017 Jun 27.
    • Review
    • A novel Ubc9 -dependent pathway regulates SIRT1- ER-α Axis and BRCA1-associated TNBC lung metastasis.
    • Xu J, Shumate C, Qin Y, Reddy V, Burnam Y, Lopez V, Okoli J, P Reddy ES, Rao VN.
    • Integr Mol Med. 2017 Aug;4(4). doi: 10.15761/IMM.1000298. Epub 2017 Jul 28.
    • Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes.
    • Jiang D, Turner B, Song J, Li R, Diehn M, Le QT, Khatri P, Koong AC.
    • JCO Precis Oncol. doi: 10.1200/PO.16.00073. Epub 2017 Jul 26.
    • NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    • Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.
    • Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.
    • Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    • Li B, Ní Chonghaile T, Fan Y, Madden S, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn SC, Jirstrom K, Caldas C, O'Connor D, Gallagher WM.
    • Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.
    • Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding.
    • Irmejs A, Loza P, Skuja E, Gardovskis J.
    • Cureus. 2017 Jul 10;9(7):e1455. doi: 10.7759/cureus.1455.
    • Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
    • Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.
    • Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.
    • Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer.
    • Kota K, Puhalla S.
    • Cureus. 2017 Jul 4;9(7):e1424. doi: 10.7759/cureus.1424.
    • Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
    • Chen YH, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD, Radovich M.
    • NPJ Breast Cancer. 2017 Jul 3;3:24. doi: 10.1038/s41523-017-0028-4. eCollection 2017.
    • Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    • Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann EA, Hartman AR, Ford JM, Telli ML.
    • Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.
    • Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.
    • Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa A, Goldenberg DM.
    • Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.
    • Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
    • Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT.
    • Breast Cancer Res Treat. 2017 Jul;164(1):57-67. doi: 10.1007/s10549-017-4233-5. Epub 2017 Apr 17.
    • MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    • Chen LL, Zhang ZJ, Yi ZB, Li JJ.
    • Br J Cancer. 2017 Jun 27;117(1):78-88. doi: 10.1038/bjc.2017.150. Epub 2017 Jun 1.
    • Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
    • Denkert C, Liedtke C, Tutt A, von Minckwitz G.
    • Lancet. 2017 Jun 17;389(10087):2430-2442. doi: 10.1016/S0140-6736(16)32454-0. Epub 2016 Dec 7.
    • Review
    • Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer.
    • Asghar U, Barr AR, Cutts R, Beaney M, Babina IS, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, Pearson A, Herrera-Abreu MT, Bakal C, Turner NC.
    • Clin Cancer Res. 2017 Jun 12. pii: clincanres.0369.2017. doi: 10.1158/1078-0432.CCR-17-0369. [Epub ahead of print]
    • Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
    • Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.
    • Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.
    • Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
    • Jin J, Zhang W, Ji W, Yang F, Guan X.
    • Cancer Biol Ther. 2017 Jun 3;18(6):369-378. doi: 10.1080/15384047.2017.1323582. Epub 2017 May 11.
    • DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
    • De Gregoriis G, Ramos JA, Fernandes PV, Vignal GM, Brianese RC, Carraro DM, Monteiro AN, Struchiner C, Suarez-Kurtz G, Vianna-Jorge R, de Carvalho MA.
    • Cancer Biol Ther. 2017 Jun 3;18(6):439-449. doi: 10.1080/15384047.2017.1323590. Epub 2017 May 5.
    • Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
    • Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B.
    • Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6.
    • A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    • Tseng LM, Chiu JH, Liu CY, Tsai YF, Wang YL, Yang CW, Shyr YM.
    • Breast Cancer Res Treat. 2017 Jun;163(2):241-254. doi: 10.1007/s10549-017-4195-7. Epub 2017 Mar 15.
    • Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).
    • Vadaparampil ST, Christie J, Donovan KA, Kim J, Augusto B, Kasting ML, Holt CL, Ashing K, Halbert CH, Pal T.
    • Breast Cancer Res Treat. 2017 Jun;163(2):331-342. doi: 10.1007/s10549-017-4173-0. Epub 2017 Mar 3.
    • Olaparib for the treatment of breast cancer.
    • Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.
    • Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21.
    • Review
    • The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    • Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.
    • BMC Cancer. 2017 May 12;17(1):329. doi: 10.1186/s12885-017-3283-8.
    • Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.
    • Yeong J, Thike AA, Lim JC, Lee B, Li H, Wong SC, Hue SS, Tan PH, Iqbal J.
    • Breast Cancer Res Treat. 2017 May;163(1):21-35. doi: 10.1007/s10549-017-4161-4. Epub 2017 Feb 23.
    • Practical Approach to Triple-Negative Breast Cancer.
    • Gadi VK, Davidson NE.
    • J Oncol Pract. 2017 May;13(5):293-300. doi: 10.1200/JOP.2017.022632.

    Related:

    Commentary, Review:

    Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer

    Free Medscape version: Practical Approach to Triple-Negative Breast Cancer. Medscape

    • Triple-Negative Breast Cancer: Current Practice and Future Directions.
    • Costa RLB, Gradishar WJ.
    • J Oncol Pract. 2017 May;13(5):301-303. doi: 10.1200/JOP.2017.023333.
    • Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer.
    • Gruber JJ, Telli ML.
    • J Oncol Pract. 2017 May;13(5):305-307. doi: 10.1200/JOP.2017.023341.

    Related:

    Review:

    Practical Approach to Triple-Negative Breast Cancer.

    • Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    • El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C.
    • Mol Carcinog. 2017 May;56(5):1383-1394. doi: 10.1002/mc.22596. Epub 2017 Mar 6.
    • Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
    • Solzak JP, Atale RV, Hancock BA, Sinn AL, Pollok KE, Jones DR, Radovich M.
    • NPJ Breast Cancer. 2017 Apr 26;3:17. doi: 10.1038/s41523-017-0016-8. eCollection 2017.
    • Study Reveals Treatment Strategy for Triple-Negative Breast Cancer.
    • Mateusz Opyrchal
    • OncoTherapy Network. Breast Cancer Targets, AACR 2017. 2017 Apr 20.
    • Video
    • E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
    • Liao L, Song M, Li X, Tang L, Zhang T, Zhang L, Pan Y, Chouchane L, Ma X.
    • Cancer Res. 2017 Apr 15;77(8):2090-2101. doi: 10.1158/0008-5472.CAN-16-2409. Epub 2017 Mar 22.
    • Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.
    • Chen F, Pu F.
    • Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017.
    • BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    • Domagala P, Hybiak J, Cybulski C, Lubinski J.
    • Int J Cancer. 2017 Apr 1;140(7):1545-1550. doi: 10.1002/ijc.30570. Epub 2017 Jan 24.
    • Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells.
    • Bassey-Archibong BI, Rayner LG, Hercules SM, Aarts CW, Dvorkin-Gheva A, Bramson JL, Hassell JA, Daniel JM.
    • Cell Death Dis. 2017 Mar 23;8(3):e2689. doi: 10.1038/cddis.2017.92.
    • The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
    • Castrellon AB, Pidhorecky I, Valero V, Raez LE.
    • Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017.
    • A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
    • Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.
    • Clin Cancer Res. 2017 Mar 7. doi: 10.1158/1078-0432.CCR-16-3055. [Epub ahead of print]
    • Therapeutic Strategies in Triple-Negative Breast Cancer.
    • Paradiso A, Singer CF.
    • Breast Care (Basel). 2017 Mar;12(1):6-7. doi: 10.1159/000460238. Epub 2017 Feb 28.

    Related:

    Review:

    Biological Subtypes of Triple-Negative Breast Cancer.

    Review:

    Germline Mutations in Triple-Negative Breast Cancer.

    Review:

    Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.

    • Biological Subtypes of Triple-Negative Breast Cancer.
    • Hubalek M, Czech T, Müller H.
    • Breast Care (Basel). 2017 Mar;12(1):8-14. doi: 10.1159/000455820. Epub 2017 Feb 20.

    Related:

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • Germline Mutations in Triple-Negative Breast Cancer.
    • Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK.
    • Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24.

    Related:

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.
    • Andreopoulou E, Kelly CM, McDaid HM.
    • Breast Care (Basel). 2017 Mar;12(1):21-28. doi: 10.1159/000455821. Epub 2017 Feb 7.

    Related:

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • New Therapeutic Strategies for Triple-Negative Breast Cancer.
    • Székely B, Silber AL, Pusztai L.
    • Oncology (Williston Park). 2017 Feb 15;31(2). pii: 221108.
    • Review
    • PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    • Song W, Tang L, Xu Y, Xu J, Zhang W, Xie H, Wang S, Guan X.
    • Sci Rep. 2017 Feb 8;7:42319. doi: 10.1038/srep42319.
    • BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    • Sinha A, Paul BT, Sullivan LM, Sims H, Bastawisy AE, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.
    • Oncotarget. 2017 Feb 7;8(6):10114-10135. doi: 10.18632/oncotarget.14357.
    • Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
    • Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor C, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell A, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner J, Mammen JM, McGinness M, Klemp JR, Amin A, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.
    • Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.
    • Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
    • Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX.
    • Breast Cancer Res Treat. 2017 Feb;161(3):491-499. doi: 10.1007/s10549-016-4062-y. Epub 2016 Dec 3.
    • miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
    • Fkih M'hamed I, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ, Kenani A.
    • Pathol Oncol Res. 2017 Jan 18. doi: 10.1007/s12253-017-0188-4. [Epub ahead of print]
    • RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    • Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha MS, Liu S.
    • Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.
    • Triple-negative breast cancer: is there a treatment on the horizon?
    • Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X.
    • Oncotarget. 2017 Jan 3;8(1):1913-1924. doi: 10.18632/oncotarget.12284.
    • The fate of BRCA1-related germline mutations in triple-negative breast tumors.
    • Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.
    • Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.
    • Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    • Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.
    • Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.
    • Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    • Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL.
    • Breast Cancer Res Treat. 2017 Jan;161(2):279-287. doi: 10.1007/s10549-016-4059-6. Epub 2016 Nov 25.
    • Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
    • Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BA, Rakha EA, Nolan CC, Ellis IO, Green AR.
    • Pathol Res Pract. 2017 Jan;213(1):27-33. doi: 10.1016/j.prp.2016.10.005. Epub 2016 Oct 25.
    • MicroRNA in breast cancer: The association with BRCA1/2.
    • Nina P, Radoslav D, Vladan B, Milan O, Esma IR.
    • Cancer Biomark. 2017;19(2):119-128. doi: 10.3233/CBM-160319.
    • Review
    • ASCO 2017: highlights in breast cancer.
    • Bartsch R, Bergen E.
    • Memo. 2017;10(4):228-232. doi: 10.1007/s12254-017-0368-7. Epub 2017 Nov 13.
    • SABCS 2016: systemic therapy for metastatic breast cancer.
    • Gampenrieder SP, Rinnerthaler G, Greil R.
    • Memo. 2017;10(2):86-89. doi: 10.1007/s12254-017-0326-4. Epub 2017 Apr 4.
    • Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
    • Liedtke C, Rody A.
    • Rev Recent Clin Trials. 2017;12(2):73-80. doi: 10.2174/1574887112666170307095945.
    • Review
    • BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    • Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M.
    • PLoS One. 2016 Dec 15;11(12):e0167016. doi: 10.1371/journal.pone.0167016. eCollection 2016.
    • Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
    • Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C.
    • PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016.
    • BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, Shida A, Waraya M, Katoh H, Enomoto T, Sengoku N, Kajita S, Hoffman RM, Watanabe M.
    • PLoS One. 2016 Dec 9;11(12):e0165721. doi: 10.1371/journal.pone.0165721. eCollection 2016.
    • Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    • Spugnesi L, Gabriele M, Scarpitta R, Tancredi M, Maresca L, Gambino G, Collavoli A, Aretini P, Bertolini I, Salvadori B, Landucci E, Fontana A, Rossetti E, Roncella M, Naccarato GA, Caligo MA.
    • Genes Chromosomes Cancer. 2016 Dec;55(12):915-924. doi: 10.1002/gcc.22389. Epub 2016 Jul 26.
    • The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    • Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, Xu J, Guan X.
    • Int J Biol Sci. 2016 Nov 25;12(12):1500-1510. eCollection 2016.
    • Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
    • Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS.
    • NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016.
    • AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.
    • Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B5,, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.
    • NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.
    • Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
    • Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.
    • Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17.
    • Review
    • Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.
    • van Harten WH, Retèl VP.
    • Ecancermedicalscience. 2016 Oct 28;10:683. eCollection 2016.
    • Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features.
    • Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, Barakat A, El Yemlahi B, Bihri H, Nourouti NG, Mechita MB.
    • BMC Womens Health. 2016 Oct 22;16(1):68.
    • Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    • Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.
    • BMC Cancer. 2016 Oct 19;16(1):811.
    • Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    • Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J.
    • Oncotarget. 2016 Oct 18;7(42):68662-68673. doi: 10.18632/oncotarget.11900.
    • Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
    • Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A.
    • J Clin Oncol. 2016 Oct 1;34(28):3400-8. doi: 10.1200/JCO.2015.65.6595. Epub 2016 Jun 20.

    Related:

    Editorial

    Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

    • Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
    • Yang L, Feng Y, Qi P, Xu S, Zhou Y.
    • J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1041-1045.
    • A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
    • Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D.
    • Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21.
    • Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    • Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D.
    • Medicine (Baltimore). 2016 Oct;95(40):e4975.
    • Biology and Management of Patients With Triple-Negative Breast Cancer.
    • Sharma P.
    • Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.
    • Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer.
    • Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.
    • Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.
    • News on the medical treatment of young women with early-stage HER2-negative breast cancer.
    • Lambertini M, Poggio F, Vaglica M, Blondeaux E, Del Mastro L.
    • Expert Opin Pharmacother. 2016 Aug;17(12):1643-55. doi: 10.1080/14656566.2016.1199685. Epub 2016 Jun 20.
    • Review
    • Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    • Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley DD, Brock IW, Cramp HE, Dotsenko O, Wilks O, Wyld L, Cross SS, Cox A
    • PLoS One. 2016 Jul 27;11(7):e0160174. doi: 10.1371/journal.pone.0160174.
    • Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    • Yang M, Teng W, Qu Y, Wang H, Yuan Q.
    • Breast Cancer Res Treat. 2016 Jul;158(2):277-86. doi: 10.1007/s10549-016-3888-7. Epub 2016 Jul 4.
    • Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    • Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.
    • Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2.
    • Do platinum salts fit all triple negative breast cancers?
    • Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F.
    • Cancer Treat Rev. 2016 Jul;48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11.
    • Review
    • BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    • Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I.
    • Eur J Surg Oncol. 2016 Jul;42(7):999-1001. doi: 10.1016/j.ejso.2016.02.246. Epub 2016 Mar 2.
    • Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
    • Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, Mazumder S.
    • Cancers (Basel). 2016 Jun 16;8(6). pii: E56. doi: 10.3390/cancers8060056.
    • Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    • Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.
    • PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
    • Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
    • Li M, Zhang J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Gene. 2016 Jun 10;584(1):26-30. doi: 10.1016/j.gene.2016.03.004. Epub 2016 Mar 5.
    • Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis.
    • Miquel-Cases A, Retèl VP, van Harten WH, Steuten LM.
    • Value Health. 2016 Jun;19(4):419-30. doi: 10.1016/j.jval.2016.01.015. Epub 2016 Apr 6.
    • Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
    • Nair RS, Kumar JM, Jose J, Somasundaram V, Hemalatha SK, Sengodan SK, Nadhan R, Anilkumar TV, Srinivas P.
    • Sci Rep. 2016 May 25;6:26631. doi: 10.1038/srep26631.
    • Triple-negative breast cancer: treatment challenges and solutions.
    • Collignon J, Lousberg L, Schroeder H, Jerusalem G.
    • Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.
    • Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'-Methodological challenges in combining miRNAs as circulating biomarkers.
    • Verderio P, Bottelli S, Lecchi M, Plebani M, Gariboldi M, Pizzamiglio S, Ciniselli CM.
    • Br J Cancer. 2016 May 10;114(10):e5. doi: 10.1038/bjc.2016.1. Epub 2016 Apr 21.

    Related:

    Response to: Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'.

    • The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    • Anders CK, Abramson V, Tan T, Dent R.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):34-42. doi: 10.1200/EDBK_159135.
    • Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
    • Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, Shabtai M, Zippel D, Gutman M, Golan T, Yosepovich A, Catane R, Modiano T, Kaufman B.
    • Breast Cancer Res Treat. 2016 May;157(1):157-65. doi: 10.1007/s10549-016-3800-5. Epub 2016 Apr 25.
    • Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
    • Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS.
    • PLoS One. 2016 Apr 14;11(4):e0153113. doi: 10.1371/journal.pone.0153113. eCollection 2016.
    • Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    • Thike AA, Tan PH, Ikeda M, Iqbal J.
    • Histopathology. 2016 Apr;68(5):702-12. doi: 10.1111/his.12801. Epub 2015 Nov 2.
    • A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
    • Buckley NE, Haddock P, De Matos Simoes R, Parkes E, Irwin G, Emmert-Streib F, McQuaid S, Kennedy R, Mullan P.
    • Oncotarget. 2016 Mar 2. doi: 10.18632/oncotarget.7865. [Epub ahead of print]
    • Genetics of triple-negative breast cancer: Implications for patient care.
    • Afghahi A, Telli ML, Kurian AW.
    • Curr Probl Cancer. 2016 Mar - Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23.
    • Review
    • Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    • Jia LY, Shanmugam MK, Sethi G, Bishayee A.
    • Anticancer Drugs. 2016 Mar;27(3):147-55. doi: 10.1097/CAD.0000000000000328.
    • Review
    • MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    • Matamala N, Vargas MT, González-Cámpora R, Arias JI, Menéndez P, Andrés-León E, Yanowsky K, Llaneza-Folgueras A, Miñambres R, Martínez-Delgado B, Benítez J.
    • Oncotarget. 2016 Feb 25. doi: 10.18632/oncotarget.7705. [Epub ahead of print]
    • Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
    • Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ.
    • NPJ Breast Cancer. 2016 Feb 24;2:16002. doi: 10.1038/npjbcancer.2016.2. eCollection 2016.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Triple-negative breast cancer: advancements in characterization and treatment approach.
    • Hurvitz S, Mead M.
    • Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239.
    • Review
    • miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
    • Zavala V, Pérez-Moreno E, Tapia T, Camus M, Carvallo P.
    • Cancer Biomark. 2016 Jan 18;16(1):99-107. doi: 10.3233/CBM-150545.
    • Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
    • Nomura H, Kataoka F, Aoki D, Jinno H, Kitagawa Y, Sato Y, Womack C, Wombwell H, Hodgson D, O'Connor M, Harbron C, Yin X.
    • Cancer Biomark. 2016 Jan 18;16(1):145-52. doi: 10.3233/CBM-150550.
    • The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    • Anders CK, Abramson V, Tan T, Dent R.
    • Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.14694/EDBK_159135.
    • BRCA1-associated triple-negative breast cancer and potential treatment for ruthenium-based compounds.
    • Hongthong K, Ratanaphan A.
    • Curr Cancer Drug Targets. 2016;16(7):606-17.
    • Review
    • 3'UTR shortening and EGF signaling: implications for breast cancer.
    • Akman HB, Oyken M, Tuncer T, Can T, Erson-Bensan AE.
    • Hum Mol Genet. 2015 Dec 15;24(24):6910-20. doi: 10.1093/hmg/ddv391. Epub 2015 Sep 22.
    • Meta-Analysis
    • Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    • Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Oda Y, Saeki H, Oki E, Maehara Y.
    • Clin Breast Cancer. 2015 Dec;15(6):498-504. doi: 10.1016/j.clbc.2015.06.009. Epub 2015 Jun 18.
    • Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
    • Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A, Chouhan R, Sarkar DK.
    • Indian J Surg Oncol. 2015 Dec;6(4):378-83. doi: 10.1007/s13193-015-0449-1. Epub 2015 Aug 21.
    • Optimal surgical management for high-risk populations.
    • King TA, Pilewskie M, Morrow M.
    • Breast. 2015 Nov;24 Suppl 2:S91-5. doi: 10.1016/j.breast.2015.07.022. Epub 2015 Oct 1.
    • Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
    • Stover DG, Winer EP.
    • Breast. 2015 Nov;24 Suppl 2:S132-5. doi: 10.1016/j.breast.2015.07.032. Epub 2015 Aug 5.
    • SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
    • Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.
    • Breast Cancer Res Treat. 2015 Nov;154(2):351-357. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4.
    • Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
    • Guo T, Ren Y, Wang B, Huang Y, Jia S, Tang W, Luo Y.
    • Mol Clin Oncol. 2015 Nov;3(6):1353-1360. Epub 2015 Aug 11.
    • Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    • Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.
    • Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
    • BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    • Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S.
    • Mol Oncol. 2015 Oct;9(8):1528-38. doi: 10.1016/j.molonc.2015.04.011. Epub 2015 May 7.
    • CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015-Still in the Ballpark.
    • Narod SA, Dent RA, Foulkes WD.
    • Clin Cancer Res. 2015 Sep 1;21(17):3813-4. doi: 10.1158/1078-0432.CCR-14-3122.

    Related:

    Triple-negative breast cancer: clinical features and patterns of recurrence.

    • An overview of triple negative breast cancer for surgical oncologists.
    • Sharma S, Barry M, Gallagher DJ, Kell M, Sacchini V.
    • Surg Oncol. 2015 Sep;24(3):276-83. doi: 10.1016/j.suronc.2015.06.007. Epub 2015 Jun 12.
    • Review
    • Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.
    • Miquel-Cases A, Steuten LM, Retèl VP, van Harten WH.
    • Breast. 2015 Aug;24(4):397-405. doi: 10.1016/j.breast.2015.03.002. Epub 2015 Apr 28.
    • Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.
    • Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer P.
    • Am J Cancer Res. 2015 Jun 15;5(7):2330-43. eCollection 2015.
    • Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
    • Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM.
    • J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.
    • TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    • Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.
    • J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.
    • A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.
    • Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A.
    • NPJ Breast Cancer. 2015 Jun 2;1:15003. doi: 10.1038/npjbcancer.2015.3. eCollection 2015.
    • Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
    • Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.
    • Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.
    • Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
    • Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A.
    • Br J Cancer. 2015 May 26;112(11):1751-9. doi: 10.1038/bjc.2015.143. Epub 2015 Apr 23.
    • Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
    • Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.
    • Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.
    • Therapies for triple negative breast cancer.
    • Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.
    • Expert Opin Pharmacother. 2015 May;16(7):983-98.
    • Review
    • Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
    • Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK.
    • Mol Cancer Ther. 2015 Apr;14(4):920-30. doi: 10.1158/1535-7163.MCT-14-0474.
    • Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    • Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.
    • PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.
    • Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.
    • Asleh-Aburaya K, Fried G.
    • Springerplus. 2015 Mar 15;4:132. doi: 10.1186/s40064-015-0900-3. eCollection 2015.
    • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    • Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    • Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.
    • Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    • Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    • BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.
    • Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
    • Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Ann Oncol. 2015 Mar;26(3):523-8. doi: 10.1093/annonc/mdu559. Epub 2014 Dec 5.
    • BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    • Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.
    • Gene. 2015 Feb 10;556(2):163-9. doi: 10.1016/j.gene.2014.11.047. Epub 2014 Nov 22.
    • High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.
    • Kalniete D, Nakazawa-Miklaševiča M, Štrumfa I, Āboliņš A, Irmejs A, Gardovskis J, Miklaševičs E.
    • Hered Cancer Clin Pract. 2015 Feb 8;13(1):7. doi: 10.1186/s13053-015-0028-z. eCollection 2015.
    • BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    • Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.
    • Clin Breast Cancer. 2015 Feb;15(1):80-5. doi: 10.1016/j.clbc.2014.08.003. Epub 2014 Sep 28.
    • Subtyping of triple-negative breast cancer: Implications for therapy.
    • Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.
    • Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16.
    • Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
    • Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, Wu J, Shao Z.
    • Int J Cancer. 2015 Jan 1;136(1):204-11. doi: 10.1002/ijc.28966. Epub 2014 May 23.
    • Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.
    • Zhang L, Fang C, Xu X, Li A, Cai Q, Long X.
    • Biomed Res Int. 2015;2015:357485. doi: 10.1155/2015/357485. Epub 2015 Jan 28.
    • Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
    • Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R.
    • Crit Rev Oncog. 2015;20(5-6):373-90. doi: 10.1615/CritRevOncog.v20.i5-6.100.
    • Review
    • [Triple Negative Breast Cancer].
    • Navrátil J, Fabian P, Palácová M, Petráková K, Vyzula R, Svoboda M.
    • Klin Onkol. 2015;28(6):405-15.
    • Review, [Article in Czech]
    • Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    • Toffoli S, Bar I, Abdel-Sater F, Delrée P, Hilbert P, Cavallin F, Moreau F, Van Criekinge W, Lacroix-Triki M, Campone M, Martin AL, Roché H, Machiels JP, Carrasco J, Canon JL.
    • Breast Cancer Res. 2014 Nov 22;16(6):466. doi: 10.1186/s13058-014-0466-y.
    • Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
    • Danza K, De Summa S, Pilato B, Carella M, Palumbo O, Popescu O, Paradiso A, Pinto R, Tommasi S.
    • J Transl Med. 2014 Nov 19;12(1):319. doi: 10.1186/s12967-014-0319-6.
    • Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
    • Audeh MW.
    • Pharmgenomics Pers Med. 2014 Oct 3;7:307-16. doi: 10.2147/PGPM.S39765. eCollection 2014.
    • VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer.
    • Castilla MÁ, López-García MÁ, Atienza MR, Rosa-Rosa JM, Díaz-Martín J, Pecero ML, Vieites B, Romero-Pérez L, Benítez J, Calcabrini A, Palacios J.
    • Endocr Relat Cancer. 2014 Aug;21(4):587-99. doi: 10.1530/ERC-13-0485. Epub 2014 Jun 2.
    • Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    • Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.
    • Oncotarget. 2014 Jul 30;5(14):5637-50.
    • Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
    • Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, Garber JE.
    • Breast Cancer Res Treat. 2014 Jul;146(1):175-82. doi: 10.1007/s10549-014-2995-6. Epub 2014 May 18.
    • Systemic treatment strategies for triple-negative breast cancer.
    • Yadav BS, Sharma SC, Chanana P, Jhamb S.
    • World J Clin Oncol. 2014 May 10;5(2):125-33. doi: 10.5306/wjco.v5.i2.125.
    • INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
    • Sun Y, Ding H, Liu X, Li X, Li L.
    • Tumour Biol. 2014 May;35(5):4469-77. doi: 10.1007/s13277-013-1589-y. Epub 2014 Jan 14.
    • BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    • Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R.
    • Cancer Chemother Pharmacol. 2014 Apr;73(4):771-8. doi: 10.1007/s00280-014-2404-1. Epub 2014 Feb 14.
    • Triple-negative breast cancer: molecular subtypes and targeted therapy.
    • Hirshfield KM, Ganesan S.
    • Curr Opin Obstet Gynecol. 2014 Feb;26(1):34-40. doi: 10.1097/GCO.0000000000000038.
    • Review
    • Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome.
    • Sullivan HC, Oprea-Ilies G, Adams AL, Page AJ, Kim S, Wang J, Cohen C.
    • Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):17-23. doi: 10.1097/PAI.0b013e318281148e.
    • Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    • Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.
    • Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.
    • Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    • De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    • Neoplasia. 2014 Jan;16(1):43-72.
    • Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
    • Telli M.
    • Am Soc Clin Oncol Educ Book. 2014:e37-42. doi: 10.14694/EdBook_AM.2014.34.e37.
    • Tackling the diversity of triple-negative breast cancer.
    • Turner NC, Reis-Filho JS.
    • Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915.
    • [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
    • Nowacka-Zawisza M, Krajewska WM.
    • Postepy Hig Med Dosw (Online). 2013 Nov 26;67:1090-7.
    • PARP inhibitors are not all equal.
    • Dent P.
    • Cancer Biol Ther. 2013 Oct 1;14(10):873-4. doi: 10.4161/cbt.26160. Epub 2013 Aug 26.

    Related:

    Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.

    • Targeted therapy for breast cancer.
    • Mohamed A, Krajewski K, Cakar B, Ma CX.
    • Am J Pathol. 2013 Oct;183(4):1096-112. doi: 10.1016/j.ajpath.2013.07.005. Epub 2013 Aug 27.
    • Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody.
    • Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G.
    • Mol Cancer Ther. 2013 Oct;12(10):2043-54. doi: 10.1158/1535-7163.MCT-13-0108. Epub 2013 Jul 19.
    • BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    • Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):205-12. doi: 10.1007/s10549-013-2693-9. Epub 2013 Sep 13.
    • A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.
    • Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.
    • Triple-negative breast cancer: new perspectives for novel therapies.
    • Mahamodhossen YA, Liu W, Rong-Rong Z.
    • Med Oncol. 2013 Sep;30(3):653. doi: 10.1007/s12032-013-0653-1. Epub 2013 Jul 4.
    • Review
    • Relapsed triple-negative breast cancer: challenges and treatment strategies.
    • Guarneri V, Dieci MV, Conte P.
    • Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6.
    • Review
    • The management of early-stage and metastatic triple-negative breast cancer: a review.
    • Anders CK, Zagar TM, Carey LA.
    • Hematol Oncol Clin North Am. 2013 Aug;27(4):737-49, viii. doi: 10.1016/j.hoc.2013.05.003. Epub 2013 Jun 18.
    • Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
    • Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y.
    • Ann Oncol. 2013 Jun;24(6):1498-505. doi: 10.1093/annonc/mdt011. Epub 2013 Feb 13.
    • Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    • Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ.
    • Cancer Biol Ther. 2013 Jun;14(6):537-45. doi: 10.4161/cbt.24349.

    Related:

    Comment:

    PARP inhibitors are not all equal.

    • Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review.
    • Kandula M, Ch KK, Ys AR.
    • World J Oncol. 2013 Jun;4(3):137-141. doi: 10.4021/wjon681e. Epub 2013 Jul 15.
    • Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    • Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM.
    • Br J Cancer. 2013 May 28;108(10):2172-7. doi: 10.1038/bjc.2013.144. Epub 2013 Apr 4.
    • [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
    • Gonçalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P, Bertucci F.
    • Bull Cancer. 2013 May;100(5):453-64. doi: 10.1684/bdc.2013.1740.
    • Review, [Article in French]
    • Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis.
    • Liu M, Mo QG, Wei CY, Qin QH, Huang Z, He J.
    • Oncol Lett. 2013 Mar;5(3):983-991. Epub 2012 Dec 28.
    • Updates in the treatment of basal/triple-negative breast cancer.
    • Shastry M, Yardley DA.
    • Curr Opin Obstet Gynecol. 2013 Feb;25(1):40-8. doi: 10.1097/GCO.0b013e32835c1633.
    • Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
    • Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.
    • Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.
    • Triple Negative Breast Cancer - An Overview.
    • Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ, Reddy SP, Rao VN.
    • Hereditary Genet. 2013;2013(Suppl 2). pii: 001.
    • Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
    • Nowsheen S, Cooper T, Stanley JA, Yang ES.
    • PLoS One. 2012;7(10):e46614. doi: 10.1371/journal.pone.0046614. Epub 2012 Oct 11.
    • Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.
    • Sousa B, Cardoso F.
    • Ann Oncol. 2012 Sep;23 Suppl 10:x237-42.
    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Related:

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • Locoregional treatments for triple-negative breast cancer.
    • Eiermann W, Vallis KA.
    • Ann Oncol. 2012 Aug;23 Suppl 6:vi30-4.
    • Neoadjuvant treatments for triple-negative breast cancer (TNBC).
    • von Minckwitz G, Martin M.
    • Ann Oncol. 2012 Aug;23 Suppl 6:vi35-9.
    • Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.
    • André F, Zielinski CC.
    • Ann Oncol. 2012 Aug;23 Suppl 6:vi46-51.
    • Emerging targeted therapies in triple-negative breast cancer.
    • Crown J, O'Shaughnessy J, Gullo G.
    • Ann Oncol. 2012 Aug;23 Suppl 6:vi56-65.
    • Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    • Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.
    • Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.
    • Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    • Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R.
    • Anticancer Agents Med Chem. 2012 Jul 1;12(6):672-7.
    • Review
    • Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    • Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.
    • Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.
    • Triple-negative breast cancer: are we making headway at least?
    • Arnedos M, Bihan C, Delaloge S, Andre F.
    • Ther Adv Med Oncol. 2012 Jul;4(4):195-210. doi: 10.1177/1758834012444711.
    • Molecular oncology: The positive in the negative.
    • Powell K.
    • Nature. 2012 May 30;485(7400):S52-3. doi: 10.1038/485S52a.
    • News

    Related:

    Letter:

    Tumours: Less lactation may explain cancer rise.

    • Dissecting the heterogeneity of triple-negative breast cancer.
    • Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M.
    • J Clin Oncol. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Epub 2012 Mar 26.
    • Review
    • [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].
    • Masuda N, Yasojima H, Mizutani M, Yamamura J.
    • Gan To Kagaku Ryoho. 2012 Apr;39(4):512-8.
    • Review, [Article in Japanese]
    • Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.
    • Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G.
    • Breast. 2012 Feb;21(1):20-6. doi: 10.1016/j.breast.2011.09.006. Epub 2011 Oct 8.
    • Review
    • Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.
    • Hiller DJ, Chu QD.
    • Int J Breast Cancer. 2012;2012:829315. doi: 10.1155/2012/829315. Epub 2011 Oct 25.